11 & 12 january 2014 kompleks eureka

TRANSFORMING ANTI-CANCER RESEARCH & KNOWLEDGE FROM UNIVERSITY, INDUSTRY & COMMUNITY INTO SOCIETAL BENEFITS & BEYOND

11th & 12th JANUARY 2014 KOMPLEKS EUREKA

1

First Printing January 2014 © Universiti Sains Malaysia All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic, mechanical, including photocopying, recording or by any other information storage and retrieval system without written permission from the Chairperson of “The World AntiCancer Congress & Exhibition 2014”. Published by: Universiti Sains Malaysia In collaboration with: Penerbit Universiti Sains Malaysia Printed by: Vanda Dynamic Enterprise Editor: Khoo Boon Yin Assistant Editor: Chew Ai Lan Aziana Ismail Shim Siang Yian Benjamin Khoo Wu Yang

2

THE WORLD ANTI-CANCER CONGRESS & EXHIBITION 2014

Chairperson’s Foreword Committee

CONTENTS

Congress Program At A Glance Plenary Lectures Exhibitions Poster Presentations Memo Advertisement Acknowledgements

3

CHAIRPERSON’S FOREWORD If I liken “The World Anti-Cancer Congress & Exhibition 2014" as a standing "tree", then we took two years to cultivate it. This "tree" was seeded after the "Universiti Sains Malaysia (USM)-Academia Sinica (AS) Taiwan Research Collaboration Workshop" in 2011. In the process of cultivation, this "tree" has been attacked with wilt disease and other problems. A fruitful meeting with the Malaysian Anti-Cancer Association (MACA) had led to their absolute support in the growth of the “tree”. Subsequently, “The World Anti-Cancer nd Congress & Exhibition 2014” came into existence where initially it was known as “2 World Anti-Cancer Congress & Exhibition (English version). Unlike its predecessor “2012 First (Malaysia) World Anti-Cancer Congress & Exhibition (Mandarin version)”, the event will be held for the first time at Universiti Sains Malaysia (USM). It is my great pleasure and honour to be appointed by USM and MACA to conduct this event. USM is one of the biggest universities in terms of enrolment in Malaysia, with missions focusing on the issues of a sustainable society, humanity and the future of humankind. Based on these overarching principles, USM has been chosen by the Malaysian Ministry of Higher Education (MOHE) to implement the Accelerated Programme of Excellence (APEX) under its auspices in 2008. This event aims to provide a platform for people working on anti-cancer to exchange knowledge, information, technology and experience of modern medicines, as well as traditional and complementary medicines, in search of new solutions for treating and preventing human cancers. In addition, this event is organized in line with the principal objective of the university’s Division of Industry & Community Network (DICN): educating and leading the University, Industry and Community by promoting sustainable development and transformation. We truly believe that the congress will be a highly rewarding international event for every participant and will be able to convey information on the development of the healthcare sector to the society. Finally, on behalf of the congress organizing committee members, I would like to extend our heartfelt appreciation for your valuable participation and enormous contribution that you have made towards the success of the event, and I hope this congress will be a memorable and beneficial event to you.

Sincerely, Khoo Boon Yin, Ph.D. Organizing Committee Chairperson “The World Anti-Cancer Congress & Exhibition 2014” Universiti Sains Malaysia 4

COMMITTEE Patron Y. Bhg. Prof. Dato’ Omar Osman (USM)

Advisor Y. Bhg. Prof. Dr. Wong Ching Chiong (MACA) Committee Members Chairperson

Dr. Khoo Boon Yin (USM)

Vice-Chairperson

Dr. Song Ting Siik (Lam Wah Ee Hospital)

Secretary

Ms. Shim Siang Yian (USM)

Secretariat

Dr. Chew Ai Lan (USM) Mrs. Sabariah Osman (USM) Mrs. Norizan Miswan (USM) Mrs. Nur Fatihah Mohd Zaidi (USM) Mrs. Siti Zainaf Din (USM) Ms. Siti Jannah Iman (USM) Ms. Siti Wizirah Marzuki (USM)

Scientific & Technical

Dr. Ong Ming Thong (USM) Mr. Leow Chiuan Herng (USM) Ms. Aziana ismail (USM) Mr. Teh Ban Hong (USM) Mr. Benjamin Khoo Wu Yang (USM) Mr. Mohd Nor Azam Zainol Nor (USM)

Hospitality & Publicity

Dr. Lai Ngit Shin (USM) Dr. Sasidharan Sreenivasan (USM) Dr. Oon Chern Ein (USM) Dr. Lai See Hong (Nyin Oi Tong Medical Hall) Mr. Yeap Teow Lin (Lam Wah Ee Hospital) Ms. Nur Adila Fadzil (USM)

Sponsorship

Prof. Dr. Wong Ching Chiong (MACA) Dr. Khoo Boon Yin (USM)

Protocol

Ms. Fauziah Rastam (USM) 5

CONGRESS PROGRAM AT A GLANCE Day 1

Exhibition Hall

Auditorium

08:30-09:00

Registration & Arrival of Participants

09:00-09:30

Opening & Welcoming Remarks

09:30-10:00

Souvenir Ceremony to Exhibitors

Day 2

Exhibition Hall

08:30-09:00

Auditorium

Arrival of Participants Welcoming Remarks & Plenary Lecture 9

09:00-10:00 10:00-10:40

Coffee Break

Plenary Lecture 1

10:40-11:20

Plenary Lecture 10

11:20-12:00

Plenary Lecture 2

11:20-12:00

Plenary Lecture 3: Pre-Lunch Talk

12:00-12:40

Lunch Break

12:40-14:00

Plenary Lecture 4

14:00-14:40

Plenary Lecture 5

14:40-15:20

Plenary Lecture 6

15:20-16:00

Coffee Break

16:00-16:40

Coffee Break

16:40-17:20

Plenary Lecture 7

16:40-17:20

Plenary Lecture 16

17:20-18:00

Plenary Lecture 8

17:20-18:00

Plenary Lecture 17 & Closing Remarks

12:00-12:40 12:40-14:00 14:00-14:40 14:40-15:20 15:20-16:00 16:00-16:40

Exhibition & Poster Sessions

Coffee Break

10:40-11:20 Exhibition & Poster Sessions

10:00-10:40

Plenary Lecture 11 Plenary Lecture 12: Pre-Lunch Talk Lunch Break Plenary Lecture 13 Plenary Lecture 14 Plenary Lecture 15

6

THE WORLD ANTI-CANCER CONGRESS & EXHIBITION 2014

PLENARY LECTURES

7

th

Plenary Lectures (11 January 2014) Plenary Lecture PL-01

Title • Speaker • Affiliation Neoh acupuncture for cancer pain management Neoh Choo Aun, Kaohsiung Medical University, Taiwan

PL-02

Orthosiphon stamineus solvent extract inhibits colorectal carcinoma in vivo by targeting VEGF and VEGFR activity Amin Malik Shah Abdul Majid, School of Pharmaceutical Sciences, Universiti Sains Malaysia

PL-03

Pre-lunch talk: Epigenetics and microRNAs in cancer Trisse Goh Siew Kheng, QIAGEN (M) Sdn. Bhd.

PL-04

Use of complementary and alternative medicine among cancer patients at the local hospital in Malaysia Maryam Farooqui, Universiti Teknologi Mara, Malaysia

PL-05

An update on cancer treatment and care Liu Hui-Ping, Beijing New Journey Cancer Hospital and Peking University Affiliated International Cancer Centre, China

PL-06

Cancer management Andrew Tiong Hock Seng, Malaysian Anti-Cancer Association

PL-07

How is mindfulness relevant to cancer recovery? Yeoh Kar Kheng, School of Chemical Sciences, Universiti Sains Malaysia

PL-08

HPV E6/E7 head-neck cancer screening test from saliva using branched DNA technology Bui Dinh Thuan, i-DNA Biotechnology (M) Sdn. Bhd.

8

PL-01 Neoh acupuncture for cancer pain management Neoh Choo Aun, Taiwan Associate Professor Department of Healthcare Administration & Medical Informatics Kaohsiung Medical University, Taiwan Clinical Professor & Director Research Department of Pingtung Christian Hospital, Taiwan Director Community Health Department & Pain Clinic, Pingtung City, Taiwan Email: [email protected]

Biodata Dr. Neoh is currently a Clinical Professor and the Director of Research Department of Pingtung Christian Hospital, Taiwan. At the same time, he is also the Director of Community Health Department and Pain Clinic in Pingtung City, Taiwan. He is an expert in anaesthesia, pain management, East-West-Native Integration Medicine, scalp acupuncture for stroke rehabilitation, hospice care, acupuncture, respiratory care, intensive care, brain death determination, community health, health promotion, hospital management, Health Promoting Hospital and Healthy City.

Abstract Neoh Acupuncture System is a Clinical Pain Management Skill Teaching Model, the Modified SPICES Mode. It is a clinical practice system that integrates the East or traditional Chinese acupuncture system and Western Medicine dry needling system, which include the Travell and Simons’ Trigger points manual on myofascial pain syndrome dry needling with acupuncture needle, Dr. Felix Mann’s periosteal needling method and any native effective needling method such as foot massage. Additionally, it also includes the various micro-acupuncture system, especially the scalp acupuncture system, auricular acupuncture system and tongue acupuncture. So, it is also called the East-West-Native Integrated Global Medicine. When these systems cannot totally resolve the patient problem,『Neoh Acupuncture Technique 』will add in the dynamic intradermal needling method and the『X』cross side needling method and etc. It always follows the sequence of pain pattern differential diagnosis, meridian and Zhang Fu diagnosis, patient body language, feeling, sensation and does the PDCA analysis until patient’s pain and problem are solved. Never consider patient as neurosis, but belief in the patient feeling and concern, and 9

stress on patient body language, feeling, patient’s family and friend’s inputs, which give more clues to the correct determination of point or acupuncture point to be needled. Not only stress the importance of doctor left hand to palpate for trigger points or acupuncture points, but also stress the importance of doctor right hand fingertip sensation to prevent any accident puncture of the lung, heart or arteries. I apply this Neoh Acupuncture System for cancer pain management. This model is patient-centred and not equipment- and test-centred. What the patients tell us and their body language are more important than the CT and MRI. We firmly belief that a patient is always right. We treat the patient with personalized and specific treatment. We are full heartedly concerned about what our patients tell us, their worries, suffering, needs and not only “complaints”. Problem-based treatment does not only consider patient complaints on their suffering, but also take serious consideration on their family inputs about the patient too. Clinical-based pain pattern and visual analogue scale may be beneficial, but not enough if other factors are not considered. Other factors including body language, which is very crucial; clinical symptoms and signs; history; Ben Zheng; palpation; fingertip sensation; feeling and “hands-on treatment”. Evaluate the condition of the patient if it is improved after treatment. Consider anything that interferes with the patient in the present and not look at X-rays that show evidence of what happened years ago. Treatment-evaluation and treatment using PDCA cycle are carried out in our clinic. How this SPICES model is used in various cancer pain managements will be elaborated in more detail during the conference.

10

PL-02 Orthosiphon stamineus solvent extract inhibits colorectal carcinoma in vivo by targeting VEGF and VEGFR activity Amin Malik Shah Abdul Majid, Malaysia Associate Professor EMAN Testing & Research Laboratory Department of Pharmacology School of Pharmaceutical Sciences, Universiti Sains Malaysia Founder of Natureceuticals Sdn. Bhd. Honorary Chairman of EMAN Biodiscoveries Sdn. Bhd. Email: [email protected], [email protected]

Biodata Dr. Amin Malik Shah is currently an Associate Professor of Department of Pharmacology in School of Pharmaceutical Sciences, Universiti Sains Malaysia (USM). He runs and heads EMAN testing & research laboratory, which is a cancer research laboratory at the university. He is also the founder of Natureceuticals Sdn. Bhd. which is a pharmaceutical company that focuses on botanical drug manufacturing. At the same time Dr. Amin is also the honorary chairman of EMAN Biodiscoveries Sdn. Bhd. which is a CRO that focuses on botanical drug discovery and development. Amin received a Bachelor of Science (Chemistry & Pharmacology) in 1997 and Postgraduate Diploma in Science (Pharmacology & Toxicology) at the University of Auckland, New Zealand in 1999. In year 2001, he completed his MSc in Biopharmaceuticals at University of New South Wales (UNSW), Australia. He graduated with a PhD in the field of Molecular Pharmacology & Toxicology at UNSW in 2005. He spent most of his research at UNSW Bioanalytical Mass Spectrometry Facility (BMSF). He has worked at USM since his graduation. During his tenure at USM, Amin also periodically visited UNSW, School of Medical Sciences as a visiting lecturer for almost 5 years. He was also appointed as a visiting researcher at Division of Vascular Research, John Curtin School of Medical Research, Australian National University for a brief period followed by a visiting academic post at Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia for almost 2 years. His recent visiting appointment was at University of Western Australia School of Medicine and Pharmacology. Most of Amin’s research interest focuses on development of drugs that target angiogenesis for the treatment of cancer. Many of his research activities in this field are centred towards natural products particularly in transforming herbs into pharmaceuticals. Dr. Amin is passionate in affordable chemotherapeutic medicine 11

for the bottom billions. His laboratories and manufacturing facilities are established on the platform of lowering the cost of drug discovery and manufacturing that will translate into cheaper medicine. The facilities provide services for many researchers and companies in Malaysia and internationally.

Abstract Angiogenesis is a process of new blood vessel development and it plays crucial role in tumour growth and metastasis. Angiogenesis helps to channel essential nutrients and oxygen to cancer cells to ensure their survival. Key mediators of the angiogenesis cascade include the vascular endothelial growth factor VEGF and its tyrosine kinase receptor VEGFR. VEGF is transcribed when oxygen free radicals is present which can occur during the state of hypoxia and inflammation. Colorectal cancer is a highly angiogenesis dependent carcinoma that is closely linked to inflammation. Orthosiphon stamineus (O.s) commonly referred as Misai Kucing in Malaysia is a medicinal herb that is widely used to treat diabetes, hypertension, renal calculus and rheumatoid arthritis. CANSSUFIVE® is a standardised solvent extract of O.s that is currently being evaluated clinically for the treatment of colon cancer. In vivo studies utilising orthotopic xenograft tumour model of colon cancer treated with CANSSUFIVE® shows that the compound can inhibit tumour growth. Immunohistochemical analysis on tumour tissue samples indicates that VEGF expression was significantly down regulated and VEGFR phosphorylation was also reduced. Computer modelling studies reveals that rosmarinic acid present in the compound binds directly with VEGFR thus inhibiting its activity. The data also shows that the expression of COX2 enzyme was also significantly reduced which may have a downstream effect on VEGF expression. The study further highlights on the potential role of this compound in treating colon cancer.

12

PL-03 Pre-lunch talk: Epigenetics and microRNAs in cancer

Trisse Goh Siew Kheng, Singapore Team Leader of QIAGEN Application Lab APAC Email: [email protected]

Biodata Trisse joined QIAGEN with over 10 years of extensive molecular research experience in epigenetics and metabolic disease. Her primary interest has been in the molecular characterisation of genes harbouring epigenetic CpG methylation markers and gene polymorphism to serve as predictive biomarkers. She has over 6 publications in international journals. Prior to QIAGEN, Trisse held a senior research position in Singapore Institute for Clinical Science, a leading research institute in Singapore that links basic scientific discoveries with arena of clinical investigation by translating the results into changes in clinical practice. Trisse, as a research technologist, extensively focused on clinical trials to study the effect of d-alpha-tocopherol (Vitamin E), angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) on the endothelial and renal function of subjects with type-2 diabetes by adopting molecular techniques like miRNA, Real-Time PCR, DNA sequencing, and mass spectrophotometry. She graduated from the prestigious National University of Singapore, with a specialization in Epigenetics studies employing various technologies including the advanced Pyrosequencing technology to measure DNA methylation in clinical specimens. With her strong technical expertise and diverse experience, Trisse, a pivotal member of the QIAGEN Application lab, supports more than 100 customers across the APAC region with the development of automated solutions and assay development for client’s research and clinical diagnostic.

13

Abstract The importance of methylation and the miRNA regulatory pathways are found to be critical for cancer development. In this presentation, we will demonstrate the application of Pyrosequencing in the context for epigenetic methylation analysis. In addition, we will introduce a simple and easy-to-use real-time PCR method to individually study miRNA expression or to examine genomewide, pathway-focused or disease-focused miRNA expression profiles.

14

PL-04 Use of complementary and alternative medicine among cancer patients at the local hospital in Malaysia Maryam Farooqui, Malaysia Senior Lecturer & Pharmacist Faculty of Pharmacy Universiti Teknologi Mara (UiTM), Malaysia Email: [email protected]

Biodata Dr. Maryam is a pharmacist and a Senior lecturer at Faculty of Pharmacy, UiTM, Pulau Pinang. Her research area focuses on investigating the role of Complementary and Alternative Medicines in Oncology care. She completed her undergraduate studies at University of Karachi, Pakistan and received Bachelor in Pharmacy (B.Pharm) during the year 2000. She obtained her Masters in clinical pharmacy (M.Pharm, Clinical) from Universiti Sains Malaysia (USM) in 2005. She recently completed her doctorate (Ph.D) in pharmacy practice from Discipline of Social and Administrative Pharmacy (DSAP), School of Pharmaceutical Sciences, USM. She has been actively involved in qualitative investigations on understanding the behaviour of cancer patients towards the use of CAM for cancer and CAM use disclosure to the modern health care practitioners. She is also involved in investigating the Health Related Quality of Life (HRQoL) of cancer patients and their CAM use. Dr. Maryam has published a number of scientific papers on a variety of CAM therapies and its use among cancer patients. Currently she is involved in various CAM projects specifically on Malaysian doctors’ perceptions towards CAM and its integration into the modern health care system.

Abstract The use of Complementary and Alternative Medicines (CAM) is widespread for general health maintenance and management of disease symptoms. In Malaysia, there is evidence that a variety of CAM is used by patients with cancer. Cancer patients tend to use CAM in an attempt to reduce cancer recurrence and to lessen the side effects due to conventional therapies. Recommendations from family, reservations with western medicines and strong influence by the Malaysian cultural context are among other reasons of CAM use. The current study sought to evaluate Malaysian cancer patients’ decision making on the use of CAM and CAM disclosure 15

to the doctors for the management of their care. Patients were interviewed across three major Malaysian ethnic groups, Malay, Chinese and Indian. Thematic content analysis identified four central themes: Conceptualizing CAM, the decision making process; rationale given for selecting or rejecting CAM and barriers to CAM use. Participants generally used the term ‘traditional medicine’, referred to locally as ‘ubat kampung’, meaning medicine derived from ‘local traditions’. Mixed reactions were shown concerning the effectiveness of CAM to cure cancer and the slow progression of CAM results and treatment costs were cited as major barriers to CAM use. Concerns regarding safety and efficacy of CAM in ameliorating cancer as well as potential interactions with conventional therapies highlighted the importance of patients’ knowledge about cancer treatments. Lack of safety and efficacy of CAM therapies and sub-standard methods of preparations were among other reasons of not using CAM. The CAM usage decision making process is highly complex in nature which revolves around numerous issues such as socio-cultural background and the disease progression. The role of oncologists and other health care providers in CAM usage decision making may be critical in influencing cancer patients to adhere to evidence-based treatment regimens whilst the cancers are at early or curable stages.

16

PL-05 An update on cancer treatment and care Liu Hui Ping, China Professor, Chief of Cardiothoracic Surgery & Vice Superintendent Division of Thoracic & Cardiovascular Surgery Chang Gung University, Chang Gung Memorial Hospital, Taiwan President & Professor Beijing New Journey Cancer Hospital Peking University Affiliated International Cancer Center, China Email: [email protected]

Biodata Professor Liu started his medical education at Taiwan medical University, Taipei where he completed his medical education and was later awarded Doctor of Medicine. He received his training in general surgery and cardiothoracic surgery at Chang Gung Memorial Hospital in Taiwan and has been a well-known professor and head of the cardiothoracic surgeon and vice-superintendent in Chang Gung Memorial Hospital, Taiwan. He is also director member of Taiwan endoscopic surgical society and council member of Taiwan association of cardiothoracic surgery. He is one of the very few Taiwanese cardiothoracic surgeons who pioneered the development of minimally invasive thoracic surgery (VATS) in Asia and is an internationally well-known expert in minimally invasive lung cancer surgery. He contributed many book chapters, teaching VCD/DVD and publications related to VATS surgery in indexed journals. He currently serves on more than 15 editorial boards and guest reviewer of international journals and has been invited to be a visiting professor to many leading academic institutions in the world. His clinical practice covers the field of general thoracic surgery in pulmonary and esophageal cancer surgery, minimally invasive cancer surgery, mediastinal, pleural and lung transplantation for end-stage lung disease. Professor Liu is also the founder of the International Chinese Society of Thoracic surgery (ICSTS) and an active member of American Society of Thoracic Surgeons. He is currently the Professor and Chairman in Beijing New Journey Cancer Hospital (affiliated Cancer Center of Peking University) and continues actively to participate in minimally invasive lung cancer surgery.

17

Abstract Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumours (except in the case of leukaemia where cancer prohibits normal blood function by abnormal cell division in the blood stream). Tumours can grow and interfere with the digestive, nervous, and circulatory systems and they can release hormones that alter body function. Tumours that stay in one spot and demonstrate limited growth are generally considered to be benign. When a tumour successfully spreads to other parts of the body and grows, invading and destroying other healthy tissues, it is said to have metastasized. This process itself is called metastasis, and the result is a serious condition that is very difficult to treat. For many cancers, no definite cause is known and there is no single cause. The earlier cancer is diagnosed and treated, the better the chance of its being cured. Some types of cancer -- such as those of the skin, breast, mouth, testicles, prostate, and rectum -- may be detected by routine self-exam or other screening measures before the symptoms become serious. Most cases of cancer are detected and diagnosed after a tumour can be felt or when other symptoms develop. In a few cases, cancer is diagnosed incidentally as a result of evaluating or treating other medical conditions. Cancer diagnosis begins with a thorough physical exam and a complete medical history. Laboratory studies of blood, urine, and stool can detect abnormalities that may indicate cancer. When a tumour is suspected, imaging tests such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and fibre-optic endoscopy examinations help doctors determine the cancer's location and size. To confirm the diagnosis of most cancers, a biopsy needs to be performed in which a tissue sample is removed from the suspected tumour and studied under a microscope to check for cancer cells. Cancer treatment depends on the type of cancer, the stage of the cancer (how much it has spread), age, health status, and additional personal characteristics. There is no single treatment for cancer, and patients often receive a combination of therapies and palliative care including complementary alternative medicine (TCM). Treatments usually fall into one of the following categories: surgery, radiation, chemotherapy, immunotherapy, hormone therapy, or gene therapy. Immunotherapy aims to get the body's immune system to fight the tumour. Local immunotherapy injects a treatment into an affected area, for example, to cause inflammation that causes a tumour to shrink. Systemic immunotherapy treats the whole body by administering an agent such as the protein interferon alpha that can shrink tumours. Immunotherapy can also be considered non-specific if it improves cancer-fighting abilities by stimulating the entire immune system, and it can be considered targeted if the treatment specifically tells the immune system to destroy cancer cells. These 18

therapies are relatively young, but researchers have had success with treatments that introduce antibodies to the body that inhibit the growth of breast cancer cells. Bone marrow transplantation (hematopoietic stem cell transplantation) can also be considered immunotherapy because the donor's immune cells will often attack the tumour or cancer cells that are present in the host. There are now many combination of cancer therapies are ongoing clinical trial and hope to bring a success of control for the cancer patient in the near future.

19

PL-06 Cancer management

Andrew Tiong Hock Seng, Malaysia Professor Secretary of Malaysian Anti-Cancer Association (MACA) Email: [email protected], [email protected]

Biodata Professor Andrew Tiong obtained his Ph.D of Management at IIUCTT, Malaysia. He also obtained his M.D (AM) from Kursk State Technical University and D. Ac European Bosnia Medical Institute in Russia. Besides that, he has certification from D.Sc (Acupuncture) BCU in China and M.Ac. Research Centre of Oriental Medicine in Singapore. He was a Chartered Scientist and Mathematicians in United Kingdom. Currently, he holds a position as Secretary of Malaysian AntiCancer Association (MACA). He is the world leading authority in the optimum time theory in acupuncture. Also, he has been teaching alternative medicine for more than 20 years.

Abstract Cancer management can be done in the following four means: 1. 2. 3. 4.

Western medicine Chinese medicine Alternative medicine Holistic medicine

The following issues will be discussed during the congress 1. 2. 3. 4. 5. 6.

What is cancer? What causes cancer? How is cancer being treated? How do treatment plans work? How is cancer prevented? Conclusion 20

PL-07 How is mindfulness relevant to cancer recovery? Yeoh Kar Kheng, Malaysia Lecturer in Organic Chemistry School of Chemical Sciences Universiti Sains Malaysia Email: [email protected], [email protected]

Biodata Dr. Yeoh obtained his doctorate degree in Organic Chemistry from University of Oxford, UK. He joined the School of Chemical Sciences, Universiti Sains Malaysia (USM) as a Senior Lecturer in 2012. His fields of expertise include chemical biology (e.g. Hypoxia Inducible Factor (HIF) Hydroxylases), drug design, synthesis of smallmolecule inhibitors and natural product chemistry. In addition to his professional career, he has over 10 years of experience practising Mindfulness. He initiated and conducted the INTI International University Mindfulness Class from 2004 to 2007. At present, he is still actively involved in Mindfulness trainings, which include completing a Mindfulness-Based Cognitive Therapy (MBCT) course at Oxford Mindfulness Centre, UK. He is the founder, project leader and facilitator of USM Mindful@Sejahtera Program-A Mindfulness-based Emotional Intelligence and Wellness Program for USM and the Community; which has commenced since October 2013.

Abstract Rapidly expanding scientific evidence has demonstrated that Mindfulness-based interventions are effective in a wide range of physical and mental health applications. Mindfulness programs have achieved significant reduction in stress symptoms/mood disturbance and improvement in patients and therapists’ quality of life. It has been proven that Mindfulness-based therapies can directly benefit physical health by enhancing immune system response, promoting recovery, and inducing a sense of well-being in Mindfulness practitioners. Popular Mindfulnessbased interventions which have been widely applied in clinical settings include Mindfulness-based Stress Reductions (MBCT), Mindfulness-based Cognitive Therapy (MBCT), and Mindfulness-based Cancer Recovery. In this talk, you will learn more about (i) WHAT is Mindfulness and (ii) HOW is Mindfulness relevant to You? 21

PL-08 HPV E6/E7 head-neck cancer screening test from saliva using branched DNA technology Bui Dinh Thuan, Singapore Founder & CEO i-DNA Biotechnology (M) Sdn. Bhd. Adjunct Professor International Medical University, Kuala Lumpur, Malaysia Email: [email protected]

Biodata Dr. Bui was one of the Wellcome Trust PhD scholars in Molecular Biology, University of London from year 1991 – 1994. He furthered his post-doctoral research in cancers (Imperial Cancer Research Fund, UK), in human genetics (The Wellcome Trust, Oxford University, UK) and in basic research (Institute of Molecular and Cell Biology, Singapore) from year 1994 – 2001. In the following years until 2003, he commercialized biotechnologies owned by the Singapore government research and technology agency, A*STAR. He has founded i-DNA Biotechnology group of companies with the vision of improving the quality of life through the knowledge of science in the year 2004. Currently, i-DNA is a leading supplier of research products and services in the life science community in Malaysia. With a state-of-the-art laboratory equipped with Luminex xMAP technology and branched DNA technology, i-DNA offers a cost-effective, fast turnaround and high quality DNA, RNA and protein expression analysis service directly from any minute biological samples. In the oral presentation, i-DNA will share an example of how branched DNA technology from the bench can be applied innovatively to provide a new way of testing for head-andneck cancer in man directly from saliva, to generate diagnostic value that can help to improve the quality of life in man with the risk of head-and-neck cancer.

Abstract Human Papilloma Viruses (HPV) are DNA-based pathogens that infect the epithelial surface of the skin and mucous membranes in humans and other animals. Oncogenic strains of HPV have been associated with several human cancers including those of the cervix and anus. More recently, it has also been linked to squamous cell carcinoma of the head and neck region, specifically of the oropharynx. HPV induced oropharyngeal carcinoma has an increasing incidence in white males in the United States and Europe, and represents about 40-80% of all 22

oropharyngeal carcinomas in the USA (Marur et al 2010). Two viral oncogenes, E6 and E7, are invariably expressed in HPV-positive cancer cells. Their gene products are known to inactivate two major tumour suppressors, p53 and RB. Overtime, these effects of E6/E7 lead to the oncogenesis of infected epithelial cells in multiple locations, such as the oropharynx. HPV E6 and E7 are necessary for the oncogenic transformation, and therefore are invariably expressed in HPV induced tumours, and serve as biological markers for these tumours. Likewise, E6 and E7 expression may also function as surrogate markers to aid in prognosis assessment and evaluation of cancer response to treatment. Using branched DNA technology, a highly sensitive and specific nucleic acid hybridization assay is developed to simultaneously detect E6 and E7 mRNAs of all 14 high-risk HPV subtypes directly from saliva samples without RNA purification and reverse transcription or PCR. The assay is capable of detecting as few as 50 RNA transcript molecules and the data correlates well with the results on the same samples obtained using the current PCR method.

23

th

Plenary Lectures (12 January 2014) Plenary Lecture PL-09

Title • Speaker • Affiliation Combining Chinese and western medicines & natural therapy and Malaysian local herbs for anticancer Wong Ching Chiong, Malaysian Anti-Cancer Association

PL-10

Personalized human natural killer cell responses in cancer and infection Makoto Yawata, National University of Singapore and Brenner Centre for Molecular Medicine, Singapore

PL-11

Isolation and characterization of cytotoxic secondary metabolites of Goniothalamus spp. in Sarawak, Malaysia Fasihuddin B. Badruddin Ahmad, Universiti Malaysia Sarawak

PL-12

Pre-lunch talk: Role of nutritional therapy in reversing progression of cancer Dato' Steve Yap, DSY Wellness and Longevity Center, Malaysia

PL-13

The use of complementary and alternative medicine among Malay breast cancer survivors Suhaina Sulaiman, Universiti Kebangsaan Malaysia

PL-14

Next generation photodynamic therapy (NGPDT): Revolutionary non-invasive cancer therapy for the 21st century Lim Eng Huat, International Cancer Therapy and Regenerative Medical Centre, Petaling Jaya, Malaysia

PL-15

Comparative "OMICS" approaches for deciphering bioefficacy and molecular insights of novel phytoagents for cancer therapy Shyur Lie-Fen, Academia Sinica and National Taiwan University

PL-16

Anti-Cancer Qigong Amir Farid Isahak, Guolin Qigong Association Malaysia

PL-17

Antiproliferative activity of natural rubber latex sera on human cancer cell lines Sunderasan a/l Elumalai, Rubber Research Institute of Malaysia

24

PL-09 Combining Chinese and western medicines & natural therapy and Malaysian local herbs for anticancer Wong Ching Chiong, Malaysia Professor Founder & President of Malaysian Anti-Cancer Association (MACA) Email: [email protected], [email protected]

Biodata Professor Wong is the founder and current president of Malaysian Anti-Cancer Association (MACA). He obtained his doctorate in traditional Chinese Acupuncture and clinical oncology from Guangzhou University of Chinese Medicine. At the same time, he was honoured as honorary and visiting Professorship from several China Medical Universities. He is passionate in Chinese traditional medicine and he welcomes interested public to participate in this area.

Abstract Cancer is a terrible disease that everyone widely speaks of. If unfortunately one is infected with cancer and do not know what to do or where to seek medical attention, please do not worry or give up, there is still hope. In recent years, with the progression of the Western medicine, for the majority of patients with early stage cancer, doctors can use chemotherapy, radiation therapy, surgery, etc. to cure and eliminate most of the cancer cells. Up till now, the Western medicine treatment of cancer is still the best and the most reliable way. I strongly propose that cancer patients take up western medicine as the most basic treatment and other treatment methods to only be a supporting role. If you choose Western medicine treatment methods as the main treatment method, you should seek the advice of your physician on whether you can use other treatments as adjunctive therapy.

25

PL-10 Personalized human natural killer cell responses in cancer and infection Makoto Yawata, Japan Assistant Professor Department of Pediatrics, National University of Singapore (NUS) Principle Investigator Singapore Institute for Clinical Sciences, Agency for Science, Technology & Research Brenner Centre for Molecular Medicine Email: [email protected]

Biodata Dr. Makoto’s research interests involve aspects of human and non-human primate NK cell biology, a field he has been working in for over 15 years. His research marries his experience practicing in rheumatology, clinical immunology and pathology with cellular and molecular techniques in basic immunology. The research team places emphasis on understanding the mechanisms of human variation in NK cell responses against infection and cancer, and projects are developed through industrial and academic collaborations. Makoto was conferred his M.D. (1992) and Ph.D. (2001) in Yokohama City University School of Medicine in Japan. He subsequently conducted research in the immunogenetics of human NK cells in Stanford University School of Medicine until 2009. Makoto currently heads the natural killer (NK) cell laboratory in the Singapore Institute for Clinical Sciences and has recently joined the Department of Pediatrics in the National University of Singapore to develop immunotherapy for hematological malignancies. He functions as the Associate Editor for the journal ‘Immunology’ and is a member of the steering committee for the Singapore Non-human Primate Science Network. Academically, he organizes a training course for clinical trial design and management, and also teaches in an immunology course in the university.

26

Abstract Natural killer (NK) cells are innate lymphocytes with important roles in tumour immunosurveillance and in immunotherapy. Their responses are regulated through an intricate balance in signaling from multiple activating and inhibitory receptors expressed on the cell surface of individual NK cells. Importantly, the NK cells in the peripheral blood of human individuals vary substantially in their phenotypes and functions, effectively creating a repertoire of cells differing in their specificity and responses. Whereas many activating receptors are expressed relatively homogenously in the NK cell population, inhibitory receptor phenotypes are highly variable within the cellular repertoire of an individual and amongst humans. This heterogeneity in NK cell repertoires confers substantial variation in the anti-tumour response as well as in NK cell-based immunotherapy, such as in hematopoietic stem cell transplantation. The current understanding on the genetic and immunological factors involved in generating the vast heterogeneity in human NK cells will be described in conjunction with their potential in cancer immunotherapy.

27

PL-11 Isolation and characterization of cytotoxic secondary metabolites of Goniothalamus spp. in Sarawak, Malaysia Fasihuddin B. Badruddin Ahmad, Malaysia Professor Department of Chemistry, Faculty of Resource Science & Technology Universiti Malaysia Sarawak, Kota Samarahan, Malaysia Advisor of Malaysian Anti-Cancer Association Email: [email protected], [email protected]

Biodata Dr. Fasihuddin obtained his M.Sc. and Ph.D from the University of Salford, United Kingdom. Currently, he is a Professor in Natural Product Chemistry at Universiti Malaysia Sarawak. His main research interest covers various aspect of natural product chemistry. Secondary metabolites from terrestrial plants especially medicinal plants and also marine organisms and their biological activity have been focused throughout. Biological activities such as antioxidant, antifungal, antibacterial, toxicity of the natural product isolates and also metal complexes have been studied extensively. Essential oils from aromatic plants due to their interesting application in medicine and perfumery have also been focused. At the moment, his research area is focusing on Goniothalamus spp especially on the secondary metabolites, cytotoxicity and chemical modification of the secondary metabolites in order to enhance their activities. He is also actively involved in publication and papers that are published in international journal, national journal and also proceedings. The major area of publication is natural products chemistry focusing on the isolation, characterisation and biological activities of secondary metabolites and organometalic compounds and also their synthesis. He has published more than 180 articles to date. The publication consists of three books, editorial board for ten books, 23 articles as book chapters, translated one book, 100 journal articles (90 international journals) and 62 proceeding papers (18 international proceedings) and also referee/editors for several journals.

28

Abstract Goniothalamus spp. are widely used in traditional medicinal practices in Sarawak especially in treating diarrhoea, fever, skin diseases, as antidotes and most commonly used as postparturation aids and as abortifacient. Several Goniothalamus spp. found in Sarawak have been studied and interesting bioactive compounds have been isolated. Some of the species studied includes G. andersonii, G. borneensis, G. fasciculatus, G. kinabaluensis, G. roseus, G. sinclairianus, G. stenophyllus, G. tapisoides, G. cylindrostigma and G. velutinus. Phytochemical studies on these species resulted in the isolation of various styryl-lactones and alkaloids. For examples studies on G. roseus resulted in the isolation of various styryl-lactones such as dehydrogoniothalamin, 5-acetoxygoniothalamin, goniothalamin, goniotriol and alkaloids which has been identified as velutinam, goniothalactam and aristolactam BII; while studies on G. sinclairianus resulted in the isolation of various styryl-lactone such as goniothalamin, goniotriol, goniofupyrone, goniofufurone, goniothalesdiol, acetoxygoniothalamin and alkaloids such as goniothalactam, aristolactam AIII, aristolactam BII, N-methylaristolactam BII, 9,10-dehydro-N-metylaristolactam BII and velutinam. Extensive studies on G. cylindrostigma resulted in the isolation and characterization of goniothalamin, dehydrogoniothalamin, 5-acetoxygoniothalamin, goniotriol, (+)-altholactone and deoxygoniopypyrone, while alkaloids isolated from this plants includes methylpiperolactam, piperolactam B, aristololactam AII, aristololactam AIIIa and (-)nordicentrine. The isolated styryl-lactones and alkaloids from Goniothalamus spp. showed interesting biological activity especially cytotoxicity on various human tumour cell lines. (-)-Nordicentrine isolated from G. cylindrostigma showed strongest cytotoxicity against KB (human epidermoid carcinoma in the mouth), BC1 (human breast cancer), NCI-H187 (human lung cancer) and MCF-7 (human breast cancer) with the IC50 values of 0.4, 2.0, 0.4 and 2.9 g/mL, respectively.

29

PL-12 Pre-lunch talk: Role of nutritional therapy in reversing progression of cancer Dato' Steve Yap, MS, FICT, FAARM, FNMedP, Malaysia Complementary Medical Director of DSY Wellness & Longevity Center President of Federation of Complementary & Natural Medical Associations Malaysia President of Association of Nutritional Medicine Practitioners Malaysia Visiting Lecturer in Regenerative Medicine, Universiti Teknologi Malaysia Email: [email protected]

Biodata Dato’ Steve Yap obtained his Professional Diploma from Plaskett Nutritional Medicine College in United Kingdom followed by first Master’s degree in Metabolic and Nutritional Medicine (with honours) from University of South Florida School of Medicine. He had his second Masters’ degree in administration from University of Durham, England. He was awarded with two fellowships in Integrative Cancer Therapies from American Academy of Anti-Aging Medicine and in Anti-Aging, Regenerative Medicine, and Functional Medicine from A4M, USA. He received three board certifications on Nutritional Medicine (with distinction) from Nutritional Medicine Certification Board, WOSIAM in France; Anti-Aging Medicine (with distinction) from Anti-Aging Medical Certification Board, WOSIAM in France; and Clinical Anti-Aging Medicine from A4M in USA. He was certified by Nutritional Therapy Council in United Kingdom as Nutritional Therapy Practitioner.

Abstract Around 450BC Hippocrates, the father of Western medicine, said “Let your food be your medicine, your medicine be your food.” Today, this philosophy is being followed faithfully by those who use nutritional therapy to reverse chronic diseases. Nutritional medicine proposes dietary/ lifestyle modifications and the use of evidence-based nutraceuticals (nutrients extracted from food and plants) in raising the patients’ own defence against mutated cells, onco-viruses, and pathogens; alkalizing their internal cellular environment (cancer cells are anaerobic) to reduce malignant growth and metastasis; suppressing or neutralizing the growth-promoting effects of androgens and hormones such as estradiol, IGF-1, and insulin; promoting apoptosis of malignant cells with little or no harm to normal cells; reversing 30

anorexia, cachexia and the catabolic effects of stress hormone cortisol; oxygenating their blood and cells; detoxifying pesticides and heavy metals such as mercury and lead; inducing enhanced production of stem cells to aid repair and renewal of affected organs; reactivating their bone marrow’s production of blood cells and antibodies after chemotherapy; and improving patient’s sleep duration. These innovative directions in complementary cancer therapy have gained much praise from cancer patients and their loved ones. Nutraceuticals capable of suppressing tumour growth from initiation to malignancy and in inducing cancer apoptosis are believed to be their thousands. There is, however, insufficient funding in most countries for them to be thoroughly studied in a clinical context on a large scale due to difficulties in patenting natural formulations. The incidence of malnutrition in cancer patients ranges between 50 and 80% depending on the stage of disease, treatment they received and the types of nutritional assessment method used. According to the US National Cancer Institute, the conventional cancer therapies have led 80% of cancer patients to develop some form of clinical malnutrition. Reversing malnutrition can, therefore, be a decisive factor in reversing carcinogenesis. The author of this paper shares his decade-long experience in reversing a wide variety of cancers using largely nutritional means. His large international clientele testifies to the merits of a noninvasive and natural therapy, which mechanisms of action have been known for the past decades.

31

PL-13 The use of complementary and alternative medicine among Malay breast cancer survivors Suhaina Sulaiman, Malaysia Senior Lecturer & Dietitian Dietetics Program, Faculty of Health Sciences Universiti Kebangsaan Malaysia Email: [email protected], [email protected]

Biodata Dr. Suhaina is currently the senior lecturer and dietitian at faculty of Health Sciences, Universiti Kebangsaan Malaysia. She became ‘closed and best buddy’ to cancer after being blessed with the disease in 2009. She is one of the survivors of ovarian cancer. Her research focus in cancer work consists of various aspects from taste alteration, bone health, complementary and alternative medicine use and physical activity in relation to quality of life. She has developed recipes booklet for cancer patients on active treatment and nutrition education material for colorectal cancer patients and their caregivers. Currently, she is leading the work on the Head and Neck cancer study on development of nutritional status module for improvement of quality of life in H&N cancer survivors and their caregivers.

Abstract Complementary and alternative medicine (CAM) use is prevalent among cancer patients and survivors worldwide. Little is known about its uses in the Malay breast cancer survivors. Therefore, this study aimed at examining the pattern of CAM use among the breast cancer survivors. A convenience sample of 114 cancer survivors who completed two years of cancer treatment and undergoing follow-up treatment at the breast cancer clinic of Hospital Kuala Lumpur (HKL) and outpatient oncology clinic of Universiti Kebangsaan Malaysia Medical Centre (UKMMC) participated in this study. A self-administered questionnaire was used to obtain information on socio-demographic characteristics, cancer treatment history and use of CAM. The 2 mean age was 57.0±9.7 years with mean body mass index (BMI) of 26.8±5.2 kg/m . About 64% of the subjects were identified as CAM user with dietary supplement being the common form used followed by prayer and Malay traditional medicine. The multivitamin supplements were most consumed together with spirulina, vitamin C, evening primrose oil and herbal products. The CAM users in our study were found 32

to be older, had secondary education level and from middle household income group. Family members played a significant role in providing information together with healthcare providers, friends and relatives and printed materials and mass media. The reasons to use CAM were mainly to assist in healing of body’s inner strength, to cure cancer and to reduce stress. Only half of the subjects consulted with their physician regarding the safety of CAM use. The subjects began to use CAM while undergoing clinical treatments. Most of the subjects used CAM for more than a year. About RM100 to RM149 [USD31-46] were spent monthly on CAM by 32% of the subjects. The CAM use was found to be effective and beneficial for their disease state and they were contented with the usage of therapy. Multivariate analysis revealed that the decision to use or not to use CAM was not dependent on socio-demographic background and cancer clinical treatment history.

33

PL-14 Next generation photodynamic therapy (NGPDT): Revolutionary non-invasive cancer therapy for the 21st century Lim Eng Huat, Malaysia Chief Executive Officer (CEO) International Cancer Therapy & Regenerative Medical Centre Medical Advisor (Chinese Division) Malaysian Anti-Cancer Association Email: [email protected]

Biodata Dr. Lim obtained his Ph.D. in Naturopathy. His is the CEO of International Cancer Therapy and Regenerative Medical Centre. At the same time, he holds the position as Medical Advisor in Malaysian Anti-Cancer Association. For many years, Dr. Lim has been advocating that the best medicine against sickness and disease is our own immune system and self-healing power, along with herbs and natural supplements to complement our health. For cancer treatment methods, Dr. Lim strongly recommends the combination of Next Generation Photodynamic Therapy (NGPDT) and other non-invasive immune boosting therapies such as stem cells, nutriceutical extracts, Chinese medicine and mind and soul wellness. This will help empower the cancer patient's immune system and self-healing power to be the best weapon against cancer and reduce its recurrence to the lowest. Dr. Lim is also well versed and has many years of experience advising the use of several different stem cells therapy to boost the immune system of cancer patients, treat damaged organs and chronic degenerative diseases (e.g. heart and renal failure, lung fibrosis, liver dysfunction, Parkinson’s disease, diabetes, cardiovascular diseases, etc.). The stem cell therapies can also be used for anti-aging purposes.

34

Abstract NGPDT capitalises on the technology of conventional photodynamic therapy which has been approved by the US FDA and European EMEA medical authorities as early as 1995 to treat several types of cancer. It is a complete evolution that possesses 8 technological breakthroughs and distinct advantages over previous generations of photodynamic therapies. NGPDT is a non-invasive, non-toxic, whole body systemic treatment that targets and destroys only cancer cells. It leaves healthy cells, organs and the immune system of a patient unharmed. Positive results are proven and can be witnessed via CT scan one hour post therapy for certain types of cancer. When compared to conventional cancer treatments, the ideal combination of NGPDT and immune boosting therapies offer cancer patients a much better immune system and quality of life post treatment. This is because unlike conventional cancer treatments, whose main aim is to kill and destroy cancer cells at all cost, the main objective of the NGPDT treatment package is to empower the cancer patient’s own immune system and self-healing power to successfully manage cancer and reduce its recurrence risk to the lowest.

35

PL-15 Comparative “OMICS” approaches for deciphering bioefficacy and molecular insights of novel phytogens for cancer therapy Shyur Lie-Fen, Taiwan Professor, Vice Director & Research Fellow Agricultural Biotechnology Research Center (ABRC), Academia Sinica, Taiwan Institute of Microbiology & Biochemistry, National Taiwan University, Taiwan Email: [email protected], [email protected]

Biodata Professor Shyur is currently the Vice Director and Research Fellow in Agriculture Biotechnology Research Centre (ABRC), Academia Sinica, Taiwan since March 2008. She was the Chair/Coordinator of Molecular and Biological Agricultural Sciences Program of Taiwan International Graduate Program (TIGP-MBAS) in Academia Sinica, Taiwan. Before that, she was a joint professor in Biotechnology Center in National Chung-Hsing University in year 2003; Department of Biochemical Science and Technology in National Taiwan University in year 2008; Department of Biotechnology in National Taiwan University in year 2009 and Department of Life Science in National Taiwan Normal University in year 2012. She was appointed as Adjunct Professor at Graduate Institute of Pharmacognosy in Taipei Medical University in year 2010. She was a Ph.D holder in Agricultural Chemistry from National Taiwan University. She is actively involved in various Professional Societies such as American Chemical Society (ACS), American Society for Biochemistry and Molecular Biology (ASBMB), British Pharmacological Society (BPS), the board member in International Society of Biocatalysis and Agricultural Biotechnology (ISBAB), Society for Medicinal Plant Research (Gesellschaft für Arzneipflanzenforschung, GA), The Taiwan Genomics and Genetics Society and The Taiwan Traditional and Alternative Medicine Society. Professor Shyur serves as editorial board member in Botanical Studies, Journal of Traditional and Complementary Medicine, Guest Editor of the Journal of Advances in Botanical Research (Vol. 62), and Weeknews of Academia Sinica. Professor Shyur achievements has been recognized by many prestigious awards/honours, including The 10th National Innovation Award for Biotechnology and Medicine Industry, Significant Research Achievements of Academia Sinica (2007 and 2013), Distinguished Young Investigator Award of Academia Sinica and The Outstanding Alumni in 100-year history of Shi-Hu Elementary School in Chang-Hua 36

County, Taiwan. She was granted 15 international patents.

Abstract Phytomedicines have been used for treating or preventing diseases throughout human history. We have been conducting in exploration of Formosan medicinal plant resources, aiming to identify novel phytocompounds as candidates for further development into botanical supplements or drugs for inflammation related diseases, including cancer, acute liver hepatitis, and sepsis. Comparative “OMICS” technology platforms in combination with various in vitro and in vivo cell- and gene-based bioassays, mouse skin inflammatory and murine cancer models (mammary tumour and B16 melanoma) are employed to validate the pharmacological effects and the underlying mechanistic insights of the identified phytocompounds. The therapeutic potential of phytoagent, alone or in combination, with current clinical drug is evaluated for their potential in sensitizing the drug efficacy or reduction of side effects in tumour-bearing mice. Recently, we identified a bioactive germacranolide sesquiterpene lactone, viz. deoxyelephantopin (DET) from the Formosan medicinal plant Elephantopus scaber L. (Asteraceae), which possesses potent activity against mammary tumour growth and metastasis in syngeneic mice. Moreover, DET exhibits a more profound effect than paclitaxel (PTX) on survival rate of tumour-bearing mice. Differential proteomic profiling of DET and paclitaxel-responsive proteins in mammary adenocarcinoma TS/A cells revealed the novel effects of DET by targeting multiple oncogenic pathways and the endoplasmic reticulum (ER) machinery and suppressing proteasome activity. Further semi-organic modification of DET compound structure for improving its bioefficacy against breast cancer is on the way of study. Our results suggest that DET and its derivative have a great potential to be further developed into a lead drug candidate for breast cancer.

37

PL-16 Anti-Cancer Qigong

Dr. Amir Farid Isahak, Malaysia Founding President & Current Advisor of Guolin Qigong Association Malaysia Email: [email protected]

Biodata Dr. Amir obtained his MBBS in Queensland, Australia; MMED in Singapore; and MRCOG in London. He is a medical consultant with 35 years of medical practice. He was a lecturer at Universiti Kebangsaan Malaysia medical faculty before leaving for private practice. Although trained in Modern Medicine (practising Obstetrics/Gynaecology, Family Practice, Anti-Aging and Aesthetic Medicine), he is a firm believer and practitioner of Holistic Health, Alternative/Complementary Therapies, Energy Medicine, Nutritional Therapy, Qigong Healing and Spiritual Healing. His current interest is investigating the effectiveness of TCM herbal medicines in treating chronic diseases. At the same time he is a Qigong master, with over 20 years of experience teaching Qigong and he was the founding President of Guolin Qigong Association Malaysia for 7 years until 2005, and now serves as their advisor. Last but not least, he was a health columnist for The Star, writing on Qigong, Wellness, Nutrition and other Health topics. His “Art of Qi/Art of Healing” column was published fortnightly for over 10 years in Sunday Star Fit4Life segment.

Abstract Despite billions of dollars spent on cancer research, the outcome of cancer therapy remains one of the most disappointing in modern medicine. Advances and improvements in survival rates continue to be achieved only at a snail’s pace. There are natural therapies and natural methods which have consistently shown to be helpful. However, the lack of scientific documentation and study has caused these methods to be neglected. One of these is Qigong. Qigong is an ancient healing exercise that is part of TCM (Traditional Chinese Medicine), but most local TCM physicians do not practice it anymore. Certain Qigong exercises are known to reverse cancer. For example, Guolin Qigong exercises have 38

been adopted by many cancer recovery clubs in China. Qigong exercises involve slow, mindful movements and conscious breathing. The aim is to increase the “Qi” (life force) and improve its flow within the body. Qi flows through meridians and nourishes, vitalizes and heals all the organs of the body. Qigong healing can be achieved through self-practice or therapy by a master, or both. Case reports of local cancer survivors who cured themselves of terminal cancer and reports of some studies done in China will be presented. The experience of the Shanghai Cancer Recovery Club will be shared.

39

PL-17 Antiproliferative activity of natural rubber latex sera on human cancer cell lines Sunderasan a/l Elumalai, Malaysia Senior Research Officer Research & Innovation Department, UpstreamBiotechtumournology Unit, Rubber Research Institute of Malaysia Malaysian Rubber Board (MRB), Kuala Lumpur, Malaysia Email: [email protected]

Biodata Dr. E. Sunderasan is a senior researcher attached to the Biotechnology Unit, Malaysian Rubber Board (MRB). He obtained his Ph.D. in Plant Molecular Biology from University of Geneva, Geneva, Switzerland, in 1999. He has published widely in international scientific journals and conferences. He has received numerous awards for achievements in rubber research including the MRB best scientist award in 2010. His main research interests are in the areas of latex proteins and Hevea genetic transformation. In the last few years, he has focused on investigating anticancer property of latex sera, in collaboration with Universiti Sains Malaysia.

Abstract Natural rubber latex sera have been investigated for antiproliferative property on cancer cell lines. The present report describes fractionation of latex C-serum using cell viability assay (antiproliferative activity) as a guide to narrow down on the active constituents. Dialysis of C-serum against distilled water caused some of its constituents to precipitate, then a brief centrifugation separated their fractions – dialysed C-serum precipitate (DCP) and dialysed C-serum supernatant (DCS). Boiling of C-serum resulted in extensive precipitation; a brief centrifugation separated the boiled C-serum precipitate from their supernatant. Cell viability assay performed on human cancer-origin cell lines revealed a marked increase in antiproliferative activity in the dialysed C-serum fractions but diminished in the boiled C-serum fractions. Chromatographic separation of DCP and DCS followed by cell viability assay will shed light if sub-fractions with further improved antiproliferative activity are attainable. Molecular analyses indicated that C-serum (and its dialysed fractions) induces autoschizic death of test cancer cells.

40

THE WORLD ANTI-CANCER CONGRESS & EXHIBITION 2014

EXHIBITIONS

41

Exhibitors Exhibition Stand

Company • Organisation

ES-01

BioSpensa Resources

ES-02

Malaysian Gratitude Association (MGA)

ES-03

Genomax Technologies Sdn. Bhd.

ES-04

Befrienders Penang

ES-05

PPARs Century Sdn. Bhd.

ES-06

AntroQ Biotechnology Sdn. Bhd.

ES-07

Biomarketing Services (M) Sdn. Bhd.

ES-08

Biogreeno Sdn. Bhd.

ES-09

Asclepius Meditec (1)

ES-10

Asclepius Meditec (2)

ES-11

Whole Nature (M) Sdn. Bhd.

ES-12

Gano Excel Enterprise Sdn. Bhd.

ES-13

Prudential Assurance Malaysia Berhad

ES-14

You Dun Chao Healthcare Product Sdn. Bhd.

ES-15

Vinova Pharma Sdn. Bhd.

ES-16

NHF Natural Health Farm

ES-17

Malaysian Anti-Cancer Association (MACA) 1

ES-18

Malaysian Anti-Cancer Association (MACA) 2

ES-19

Malaysian Anti-Cancer Association (MACA) 3

ES-20

QIAGEN Biotechnology (M) Sdn. Bhd.

ES-21

The Association of Nutritional Medicine Practitioners, Malaysia

ES-22

i-DNA Biotechnology (M) Sdn. Bhd.

ES-23

National Cancer Council (MAKNA)

ES-24

MICOBF Naturopathic

42

ES-01

Company Profile BioSpensa Resources was established in Petaling Jaya, Malaysia in 2007. The name derived from the Latin word “spensa”, meaning storehouse. The aim of the company is to showcase top tier and nascent technologies for process simplification in existing workflows of life science research. Over the years, BioSpensa has built its product portfolio to become a trusted supplier to the life science industry and partners’ scientists, engineers, and researchers in South East Asia. We have four main product suites; sample storage and bio-banking, small scale bioprocessing, equipment and consumables (PCR technology focus) and liquid handling.

BioSpensa Resources NW-03-01, Cova Square Jalan Teknologi, PJU 5 Selangor Science Park 1, Kota Damansara 47810 Petaling Jaya, Selangor, Malaysia Tel: +603-6150 4612 Fax: +603-6142 4868 Email: [email protected] Website: www.biospensa.com

43

ES-02

Organisation Profile We are a non-government organization formed by a group of passionate people with a common goal in making a difference to the society for a better tomorrow and create awareness to support initiatives of environment and social matters. At MGA, we believe love is the root of all reasons. We are committed to reaching out and changing lives of many through the power of love and gratitude. We believe that the more effective way to reduce social problems is by reducing the number of orphans in the next five to ten years. And, the method is to organize for them healing activities to reduce their bad emotions inside themselves such as pain, sadness, anger, disappointment and psychological imbalance situation.

Malaysian Gratitude Association (MGA) 11A Jalan Bayan Mutiara 3, Sungai Nibong 11900 Penang, Malaysia Tel: +6017-478 8444 Email: [email protected] Website: www.mga.org.my

44

ES-03

Company Profile Genomax Technologies is founded in 2003 by a team of enterprising professional with years of experience in life science research products. Genomax Technologies’ core products cover 4 major categories of applications: bioinformatics, genomics, molecular cell biology and proteomics. We want to provide life science research communities, biotechnology & pharmaceutical companies, Southeast Asia with innovative and effective products and services. All our products and services come with excellent technical support, friendly customer service and fast delivery. Our value lies with the technical competence and dedication. We do not aim to be a general provider of laboratory consumables that merely satisfy your daily routine work. But rather all the products are carefully selected to be able to provide you with innovative avenue for your quest in biodiscovery.

Genomax Technologies Sdn. Bhd. Level 36 Menara Citibank, 165 Jalan Ampang Kuala Lumpur, 50450, Malaysia Tel: +603-2169 6245 Fax: +603-2169 6168 Email: [email protected] Website: www.genomax.com.my

45

ES-04

Organisation Profile The Befrienders is a non-profit organization modelled after Samaritans, a movement started in London in 1953. Since then, the movement has spread to about 40 countries and now has 300 centres around the world. In Malaysia, the Befrienders KL was established with the assistance of professional psychiatrists and psychologists from University Hospital Kuala Lumpur after the occurrence of th communal riots on the 13 May 1969. The primary purpose of centres is to provide emotional support to people who are suicidal, or in general distress. The service that the Befrienders offer is called befriending. We provide the service in a number of ways: phone calls, E-mail, face-to-face and outreach.

Befrienders Penang Hotline: +604-2815161, +604-2811108 Fax: 04-2822736 Service Hours: Mon - Thurs: 3.00 pm - 12.00 midnight Fri 3.00 pm - Sat 6.00 am Email: [email protected], [email protected], [email protected] Website: www.befpen.org

46

ES-05

Company Profile PPARs Century Sdn. Bhd. (formerly known as Cryto PPARs Sdn. Bhd.) was recently founded in April, 2010 as the OFFICIAL marketing arms of International Crytomonadales Biotechnology Co., Ltd (ICBC) Taiwan with the ultimate founding objectives in providing the public the AFFORDABILITY access into the latest healthcare product currently available ONLY in technologically advanced countries especially in the arena of GENETICS Technology. In PPARs Century, we believe that the public has the rights to gain access into all this products and we are COMMITTED to ensure that we provide the best healthcare products available at an AFFORDABLE price for everyone to enjoy great health and wellness.

PPARs Century Sdn. Bhd. BV03-F10, IOI Boulevard, Jalan Kenari 4 Bandar Puchong Jaya 47100 Puchong Selangor Darul Ehsan, Malaysia Tel: +603-8076 5580 Fax: +603-8076 5590 Email: [email protected] Website: www.pparcentury.com

47

ES-06

Company Profile AntroQ Biotechnology Sdn. Bhd. is the official marketing arms of Golden Biotechnology Co., Ltd Taiwan which is a drug development oriented biotechnology corporation founded in 2002, having the world’s leading drug screening platform to rapidly screen the effectiveness of components. The mission of the company is to find the ultimate solution for cancer through advance R&D focusing on BioComponent. Antroquinonol is the first single bio-component breakthrough in anticancer therapy and also known to be the world first ‘Bio-chemotherapy’ with no known side effect and completely safe for human application. The main products of the company are ANTRO ZSAINO, ANTRO LIVERTY and RASSLE which all of these products contain antroquinonol as a major component.

AntroQ Biotechnology Sdn. Bhd. th 611, 6 Floor, Block A3 Leisure Commerce Square No. 9, Jalan PJS 8/9, 46150 Petaling Jaya Selangor Darul Ehsan, Malaysia Tel: +603-7876 8008 Fax: +603-7876 3008 Website: www.antroquinonol.com.my

48

ES-07

Company Profile Biomarketing Services (M) Sdn. Bhd. (BMS) is a major local company representing a number of world renowned companies with innovative technologies in the Clinical Diagnostics and Biotech Life Science sectors. We work closely with key opinion leaders in their respective specialties in bringing technologies into Malaysia which directly improved the quality of health care to the general public. BMS is the market leader in HIV monitoring, leukaemia analysis by flow cytometer, cord blood banking, allergy diagnosis, transfusion medicine and stem cell research. Plans are also underway to acquire certain IP in medical innovation to embark on manufacturing activities.

Biomarketing Services (M) Sdn. Bhd. No. 21, Jalan 4/62A Bandar Menjalara, Kepong, 52200 Kuala Lumpur, Malaysia Tel: +603-6273 6068, +603-6273 3068 Fax: +603-6272 0093 Email: [email protected] Website: www.biomarketing.com.my

49

ES-08

Company Profile Greeno® upholds the love for nature, concerns for health, respects the integrity of business philosophy and strives to improve the lifestyle of modern society in the creation of high-quality business model, with a practical business style, excellent reputation and professional image to provide natural and efficient, safe and practical beauty health care products as part of goal to create wealth and health. Today, GREENO® through its multilevel network marketing strategy has grown into the market leader in the health food for liver, and with its excellent marketing network also spreads the business from Malaysia, throughout Taiwan, Singapore, Brunei, Hong Kong, India, Indonesia, Thailand and etc.

Bio Greeno Sdn. Bhd. No. 58 & 58-1, Jalan Puteri 2/4, Bandar Puteri, 47100 Puchong, Selangor, Malaysia Tel: +603-8063 7889 Fax: +603-8063 7797 Email: [email protected] Website: www.biogreeno.com

50

ES-09 & ES-10

Company Profile Asclepius Meditec Group is a global company having manufactures, offices and health clubs at Taiwan, Shanghai, Japan and Malaysia. The group provides medical services, medical equipment and health supplements as the adjuvant therapy for medical doctors to remove the body's Reactive Oxygen Species (ROS) and activate patients's immune system. Asclepius Meditec obtained innovation patents of its medical equipment in more than 80 countries. The medical services of Asclepius Meditec are expending in Asia and later worldwide.

Adress

51

ES-11

Company Profile Whole Nature (M) Sdn. Bhd. was established in 1995 to promote the integrity of natural complementary therapies through a group of international naturopathic expertise. Our philosophy is to develop an effective and rational therapy approach by the use of high quality traditional medicine and advanced modern therapies. We encourage people to focus on nature therapy, music therapy, food therapy, etc. We also provide comprehensive health management services through the expansion and establishment of partnerships for the purpose of creating awareness to public to take care their body and mind.

Whole Nature (M) Sdn. Bhd. 35-3, Jalan Sp 2/1 Serdang Perdana Seksyen2 43300 Seri Kembangan Selangor, Malaysia Tel: +603-8945 1099 Website: www.wholenature.com.my

52

ES-12

Company Profile Gano Excel was established in 1983 and commenced operation in 1995 as the leading industry-based nutrition Ganoderma lucidium (lingzhi) in Malaysia. Gano Excel is also the sole local MLM company that is committed to succeed “Ganoderma Nutritional Immunology” at international level. Gano Excel is one of the established and leading direct selling companies in the industry of wellness where health and wealth journey into the world to touch lives. Gano Excel manufactures and distributes a wide range of unique products ranging from food supplement, beverages, personal care, skin care to household products. Having business and market presence over 100 countries worldwide, Gano Excel continues to strive for excellence in products and market penetration.

Gano Excel Enterprise Sdn. Bhd. No. 3, 4, 5 Shahab Perdana Lebuhraya Sultanah Bahiyah 05150 Alor Setar Kedah Darul Aman, Malaysia Tel: +604-7346828 Faks: +604-7346828 Email: [email protected] Website: www.ganoexcel.com.my

53

ES-13

Company Profile Prudential was established in Malaysia in 1924 and has a long history in Asia, having maintained a presence in the region for over eighty years. Today, we are one of Asia’s leading life insurers and one of the region’s largest asset management companies. As a leading and innovative insurer, PAMB serves the savings, protection and investment needs of Malaysians by offering a full range of financial solutions through its 43 branches nationwide. With approximately 1,400 employees, PAMB is committed to helping people achieve their hopes and dreams for a brighter and financially secure future.

Prudential Assurance Malaysia Berhad Menara Prudential Ground Floor No.10, Jalan Sultan Ismail 50250 Kuala Lumpur Malaysia Contact Person (1): Ms. Kong Kui Hua Tel: 019-8851662 Email: [email protected], [email protected] Contact Person (2): Ms. Wong Lei Yuong Tel: 016-8710011 Email: [email protected], [email protected]

54

ES-14

Company Profile Established since 2012, You Dun Chao Healthcare Products Sdn. Bhd. (YDC) is gradually emerging as one of the leading herbal and nutritional supplement manufacturers in Malaysia, with the flagship UTURN brand of products which are synonymous with quality and innovation. UTURN health supplements are manufactured in compliance with Good Manufacturing Practice (GMP) approved by the Ministry of Health in Malaysia. . YDC complete with commercial scale farming of Belalai Gajah Plantation, which is You Dun Chao Herbs Farm. YDC Herbs Farm is a Cluster Herbs under New Key Economic Area Ministry of Agriculture (NKEA MOA).You Dun Chao aim to be one of the herbal international key players globally.

You Dun Chao Healthcare Products Sdn. Bhd. No. 10, Jalan Kuchai Maju 16, Kuchai Entrepreneur's Park, Off Jalan Kuchai Lama,58200 Kuala Lumpur, Malaysia Tel: +603-7982 8268, +603-7984 0071, +603-7987 8071, +603-7982 8071 Fax: +603-79823071 Email: [email protected] Website: www.youdunchao.com

55

ES-15

Company Profile Vinova Pharma Group is a progressive medical company involved in the development and marketing of products in the field of diagnostics, medical, cosmeceutical, nutraceutical and dental science for human healthcare. We endeavour to supply the latest state-of-art medical technology and innovation to the greatest majority of the population in the ASEAN region where we are active. Our focus is on the innovative therapeutic, diagnostic, cosmeceutical and nutritional products which addresses conditions in Cancer, Neurodegenerative diseases, Obstetrics & Gynaecology, Urology, Orthopaedic, Endocrinology, Fertility, Infectious diseases, Surgery & Wound healing with special interests in the field of Anti-Aging and Skin Care Biotechnology.

Vinova Pharma Sdn. Bhd. 20-2, Jalan USJ 1/1B, Regalia Business Centra, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia Tel: +603-8023 1961, +603-8023 1962 Fax: +603-8024 6963 Email: [email protected] Website: www.vinovapharma.com

56

ES-16

Company Profile Natural Health Farm has a team of Qualified Nutritional Therapist, holding Diploma in Diet & Nutrition for Complementary Therapists from ITEC, UK (International Therapy Examination Council) and Diploma in Nutritionist (Chengdu University of TCM, China). Our qualified Nutritional Therapists are led by Dr. Jessie Chung, MD (Doctor of Clinical Medicine-Oncology), who is our company’s Health Consultant. It is our mission to take care of people’s health with a very professional consultation and education of proper eating habits, healthy foods and ways to battle their sickness and weakness. We hope everyone in this world can possess healthy and blissful life.

NHF Natural Health Farm 39, Jalan Pengacara U1/48, Sekyen U1 Temasya Industrial Park, 40150 Shah Alam Selangor Darul Ehsan, Malaysia Tel: +603-5569 3721 Fax: +603-5569 3721 Email: [email protected] Website: www.nhf.com.my

57

ES-17, ES-18 & ES-19

Organisation Profile Malaysian Anti-Cancer Association (MACA) is a non-profit organization and has been officially approved by the Malaysian Registrar of Societies in May 2011 with a purpose of providing quality support services in terms of comprehensive care to cancer patients and fulfilling their families need in Malaysia to ensure patients and their loved ones do not to face cancer alone. We provide cancer information, support, and comprehensive care for cancer patients and their families. We aim to set up a charitable foundation and Cancer Rehabilitation Club, in all city and states of Malaysia.

Malaysian Anti-Cancer Association (MACA) No. 25A, Jalan 4/6, Pandan Indah 55100 Kuala Lumpur, Malaysia Tel: +6082-25 3326, +6016-898 1368, +6012-880 0790 Fax: +6082-41 1544 Email: [email protected] Website: www.cancermalaysia.org

58

ES-20

Company Profile At the forefront of the molecular biology revolution, more than 500,000 customers worldwide are using QIAGEN Sample & Assay Technologies to achieve breakthroughs based on the building blocks of life – DNA, RNA and proteins. Doctors are diagnosing diseases more precisely and quickly to guide treatment decisions. Scientists are conquering new frontiers in the understanding of life – and translating that knowledge into better medications. And experts are safeguarding the public with molecular technologies for human identification, veterinary testing and food safety. A new generation of QIAGEN innovation is creating value in the global market with solutions that were not imagined a few years ago. And so we are fulfilling our mission of making improvements in life possible.

QIAGEN Biotechnology (M) Sdn. Bhd. No. 3, Jalan Kuchai Maju Kuchai Entrepreneurs Park Off Jalan Kuchai Lama 58200 Kuala Lumpur, Malaysia Tel: 1800-80-6469 (General) Fax: +603-7981 5511 Email: [email protected] Website: www.qiagen.com

59

ES-21

Organisation Profile The Association of Nutritional Medicine Practitioners, Malaysia or Persatuan Pengamal Perubatan Nutrisi, Malaysia is a member of the Federation of Complementary and Natural Medical Associations, Malaysia, a registered practitioners’ body duly recognised for Complementary Medicine by the Traditional & Complementary Medicine Division, Ministry of Health, Malaysia.

The Association of Nutritional Medicine Practitioners, Malaysia B.08/04, 2nd Floor, Block B, Garden City Business Center, Jalan Dagang Besar, Taman Dagang, 68000, Ampang, Selangor Daruh Ehsan. Tel: +603-4270 4988 Fax: +603-4270 3678 Email: [email protected] Website: www.anmp.org.my

60

ES-22

Company Profile i-DNA Biotechnology (M) Sdn. Bhd. is a product- and service-oriented company. The primary focus of i-DNA is to develop, manufacture, market and distribute innovative products and services for applications in the area of life science, biotechnology and laboratory testing. IDT manufactures the oligo using chemical DNA synthesis machines designed and built in-house. Our customers range from small university labs of only a few scientists to global pharmaceutical companies, and everything in between. Our mission is to provide information derived from life sciences to the population through research products, services and training. Our vision is to become a leading brand provider of life sciences research products and customised services. i-DNA wants to be known as “a specialist in research solution.”

i-DNA Biotechnology (M) Sdn. Bhd. A-1-6, Pusat Perdagangan Kuchai No. 2, Jalan 1/127 Off Jalan Kuchai Lama 58200 Kuala Lumpur, Malaysia Tel : +603-7982 0322 Fax : +603-7987 4566 Email: [email protected] Website: www.i-dna.com.my

61

ES-23

Company Profile MICD Naturopathic was founded in 2010 when Iridologist and naturopath Mr KK Wong opened a small shop in Pusat Komersial Oakland II, Seremban. His objective was to help his clients to achieve “a naturally healthy mind and body” with the use of natural produced foods and supplement as remedies. His theories were based on the belief that the human body strives involuntarily to correct ill health. As an experienced iridologist, he always educates his client about the healing intelligence within the body, how the body works, how to make healthy food choices, what thoughts/beliefs need to be changed, what high quality nutritional products are needed, and other services that may assist them in achieving optimum health. Thus, the products offered and distributed by MICD Naturopathic are always in its highest quality. We know people want to have premium health, to be the best they can be, but the busy lives we lead can sometimes impede our best intentions. We use both science and naturopathic knowledge to provide the range and expertise to help you support and protect your health and well-being. Part of our brand ethos is make the best quality products available at the best price possible, to make good health affordable and accessible.

MICD NATUROPATHIC 慷之源整合医学 No.267-1 Jalan Haruan 5/7, Pusat Komersial Oakland II, 70300 Seremban, N.S. Tel: +6012-6672785 /+6012-7278258 Email: [email protected] FB: MICD Naturopathic

62

ES-24

Organisation Profile MAKNA (Majlis Kanser Nasional or the National Cancer Council) is a not-for-profit social enterprise mainly tasked to pool and to utilize every effort, expertise and financial aid from every faction of society, and to fight cancer and reduce the related pain, suffering and morbidity those cancer patients and their families often experience. MAKNA registered under the Register of Societies on 10th November 1994 and officially launched on 30th March 1995. MAKNA was founded by Dato’ Mohd Farid Ariffin. The objectives of MAKNA are to pool and utilize all efforts, expertise and finance from all sectors of the society, to fight cancer and reduce related pain, morbidity and the suffering that cancer patients undergo.

National Cancer Council (MAKNA) BG 03A & O5, Ground Floor, Megan Ambassy, No 225, Jalan Ampang, 50450 Kuala Lumpur, Malaysia. Tel: +603-2162 9178 Fax: +603-2162 9203 Email: [email protected], [email protected] Cancer Helpline: 1-800-88-62562 (MAKNA) Website: www.makna.org.my

63

THE WORLD ANTI-CANCER CONGRESS & EXHIBITION 2014

POSTER PRESENTATIONS

64

Poster Program Poster

Title • Author • Affiliation

P-01

Colon specific delivery of folic acid conjugated nanoparticles in vitro and ex vivo studies Aakanchha Jain, D.V. Kohli Dr. H.S. Gour Central University, Sagar (M.P.), India

P-02

Astaxanthin: A powerful nutrient for health Ang Fong Sim, Few Ling Ling, See Too Wei Cun, Khoo Boon Yin, Chew Ai Lan Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-03

Phenylalanine coupled solid lipid nanoparticles for brain tumour targeting Ashish Jain, Parul Kharya, Sanjay K. Jain Dr. H.S. Gour Central University, Sagar (M.P.), India

P-04

In vitro antiproliferative effect of aqueous and methanolic extracts of Malaysian medicinal plants on human thyroid cancer cells Aziana Ismail, Maizan Mohamed, Prabha Balaram, Khoo Boon Yin Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Kelantan, Malaysia

P-05

Characterization of cancer stem cell properties on CAL-27 cells Chai Yuan Lin, Ong Ming Thong, Khairani Idah Mokhtar Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-06

Cytotoxic effect of Apigenin on MCF-10A, MDA-MB-231, MCF-7 and bone marrow stem cells Chan Mooi Kwai, Chew Ai Lan, Rahmah Noordin, Khoo Boon Yin Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-07

The effect of Seaweed (Eucheuma cottonii) on mammary carcinogenesis in rats Chang Vi Sion, Teo Swee Sen UCSI University, Kuala Lumpur Campus, Malaysia

P-08

Phosphorylation of AKT and GSK3β promotes the proliferation of CAL-27 cell line Chow Tan Wei, Ong Ming Thong, Shaharum Shamsuddin Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia 65

P-09

An immuno-epidemiological survey for Schistosoma infection in Sudan and detection of colorectal cancer in Schistosoma mansoni infected patients Eshtiyag A. Abdalkareem, Tan Gim Cheong, Abdulla H. Sharif, Ahmad Babiker, Lim Boon Huat, Khoo Boon Yin Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-10

The use of Tc-99m radioisotope as early lymph diagnosis for breast cancer Fahrunissa Niniez Winner, Risha Diah Rhamadhani Polytechnic Institute of Nuclear Technology (STTN), Batan, Indonesia

P-11

Synthesis of chlorogenic acid-magnesium/aluminium layered double hydroxide nanocomposite as an anticancer nanodelivery system Farahnaz Barahuie, Mohd Zobir Hussein, Palanisamy Arulselvan, Sharida Fakurazi, Zulkarnain Zainal Materials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), Universiti Putra Malaysia, Serdang, Selangor, Malaysia

P-12

Preliminary screening of edible plants for cytotoxic activity on human colorectal carcinoma (HT29) cell line and antioxidant property Gartheka Ganasen, Yuhasini Thuraisingam, Kokila Thiagarajah, Norliza Shah Jehan Muttiah Department of Biomedicine, Universiti Tunku Abdul Rahman, Malaysia

P-13

Zerumbone inhibits murine WEHI-3B cells in BALB/c mice in vivo Heshu Sulaiman Rahman, Rasedee Abdullah, Ahmad Bustamam Abdul, Hemn Hassan Othman, Zeenathul Nazariah Allaudin, Negin Ahmadi Faculty of Veterinary Medicine, University Putra Malaysia, Serdang, Selangor, Malaysia

P-14

Anticancer activity of proteins extracted from Gynura procumbens Hew Chaw Sen, Khoo Boon Yin, Gam Lay Harn School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia

P-15

Studying the expression of PPAR and its associated genes at mRNA level in MDA-MB-231 cells treated with pioglitazone and MK886 Kalpanah Nadarajan, Chew Ai Lan, Elena Elstner, Khoo Boon Yin Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia 66

P-16

In vitro anticancer activity of traditional medicinal plants against cancer cell lines Kavitha Nowroji, Oon Chern Ein, Sasidharan Sreenivasan Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-17

Targeted delivery of anticancer drug with anti-angiogenic dendrimers for effective cancer treatment Keerti Jain, N. K. Jain Dr. H.S. Gour Central University, Sagar (M.P.), India

P-18

Latex fraction, DCS, from Hevea brasiliensis causes autoschizis cell death in human cervix adenocarcinoma cell line (HeLa) Lam Kit Lay, Yang Kok Lee, Sunderasan a/l Elumalai, Ong Ming Thong Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-19

Cytotoxic effects of Farnesol mixture of isomers and Trans,transfarnesol on HeLa cells Lee Siew Wei, Benny Wijaya, Crystale Lim Siew Ying UCSI University, Kuala Lumpur Campus, Malaysia

P-20

In vitro experimental studies on combination of Quercetin and Cisplatin for treatment of nasopharyngeal carcinoma Maelinda Daker, Munirah Ahmad, Alan Khoo Soo Beng Molecular Pathology Unit, Institute for Medical Research, Kuala Lumpur, Malaysia

P-21

Surface engineered ligand decorated multi-walled carbon nanotubes: Development and characterization for targeting potential to cancer cells Neelesh Kumar Mehra, N. K. Jain Dr. H.S. Gour Central University, Sagar (M.P.), India

P-22

Identification of natural pure compounds for therapy of nasopharyngeal carcinoma Maelinda Daker, Norhasimah Bakar, Voon Yee Lin, Munirah Ahmad, Gabriel Akyirem Akowuah, Noorlidah Abdullah, Alan Khoo Soo Beng Molecular Pathology Unit, Institute for Medical Research, Kuala Lumpur, Malaysia

P-23

Preliminary screening of Triphala herbal formulation (TPL) for cytotoxicity on human cancer cell lines and antioxidant activity Norliza Shah Jehan Muttiah, Sit Nam Weng, Sarat C. Dass, Vijanth Sagayan Asirvadam, Cheong Sok Ching Department of Biomedical Science, Universiti Tunku Abdul Rahman, 67

Malaysia

P-24

Cloning of DNA topoisomerase I into multi-copy integration vectors pOA815 and pPIC3.5K Nur Adila Fadzil, Khoo Boon Yin, Chew Ai Lan Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-25

Role of SIRT1 in mediating gemcitabine sensitivity in pancreatic cancer cells Oon Chern Ein, Carina Strell, Arne Östman, Jai Prakash Department of Oncology & Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden

P-26

A comparison study on antiproliferative properties of Selaginella doederleinii Hieron crude water extract and its sub-fractions Priscilla Jayanthi Thavamany, Ong Ming Thong Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-27

Transferrin conjugated nanoparticles for intracellular delivery of anticancer drug Satish Shilpi, Sanjay K. Jain Dr. H.S. Gour Central University, Sagar (M.P.), India

P-28

The cytotoxic activity of red onion peel extracts on human breast and oral cancer cells Siah Poh Chiew, Ong Ming Thong, Peh Kok Khiang, Khoo Boon Yin Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-29

Estimation of total flavanoids, total tannins, total phenolic content and in vitro antioxidant activity of Cedrus deodara heart wood Sourabh Jain, Aakanchha Jain, Sanjay Jain, Neelesh Malviya, Vikas Jain Bhagyoday Tirth Pharmacy College, Sagar (M.P.), India

P-30

Decoy chemokine receptors: A hope for invasive breast cancer? Tan Wee Yee, Khoo Boon Yin, Darah Ibrahim, Chew Ai Lan Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-31

Dual targeted nanoparticles for the delivery of anticancer drug to glioma cells Udita Agrawal, S.P. Vyas Dr. H.S. Gour Central University, Sagar (M.P.), India 68

P-32

Anticancer activity of Psophocarpus Tetragonolobus and Polyalthia Longifolia Vijayarathna Soundararajan, Oon Chern Ein, Sasidharan Sreenivasan Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia

P-33

Preliminary screening of Malaysian plants for cytotoxic activity on human colorectal carcinoma (HT29) cell line and in vitro analysis of the plants for antioxidant activities Yuhasini Thuraisingam, Gartheka Ganasen, Kokila Thiagarajah, Norliza Shah Jehan Muttiah Department of Biomedicine, Universiti Tunku Abdul Rahman, Malaysia

P-34

Mutagenesis and functional analysis of the pore-forming toxin from Hydra Magnipapillata Yvonne Liew Jing Mei, Hwang Jung Shan UCSI University, Kuala Lumpur Campus, Malaysia

69

P-01 Colon specific delivery of folic acid conjugated nanoparticles in vitro and ex vivo studies Aakanchha Jain, D.V. Kohli Department of Pharmaceutical Sciences, Dr. H.S. Gour Central University, Sagar (M.P.), India Email: [email protected]

Abstract Introduction: Colorectal cancer is the third leading cause of cancer death in both men and women in the US. The present chemotherapy has many side effects which can be overcome by the use of novel targeted systems. One of the leading causes of cancer is the apoptosis dysregulation (i.e. malfunctioning of caspase enzyme indirectly). Objective: The objective of the present investigation was targeting of C3A encapsulated nanoconstruct unhindered to the colon for treatment of cancer. Materials and methods: C3A-Ch NPs and C3A-FA-Ch NPs were prepared by ionic gelation method reported by Calvo et al., 1997. FaCh conjugate was prepared and analyzed for purity and conjugation surety by FTIR and NMR studies. The prepared optimized NPs were further characterized by TEM, SEM and MTT assay. The in vitro release was done in various simulated gastric fluids (Sharma et al., 2013). All the experiments were done in triplicate (n=3). Results and discussion: The peaks as observed from FTIR spectra of Ch and FA-Ch were studied and conjugation confirmed on the basis of characteristic peaks observed or disappeared for NH stretching, NH2 bending, glucosamine functional group, OH group and free C=O. C3A-FA-Ch NPs prepared by ion gelation method were found to be 247 ± 15nm in size with polydispersity index of 0.42 and percentage C3A entrapment of 61 ± 1.2%. The C3A-Ch NPs were found to be nearly spherical in shape whereas the C3A-FACh NPs were not exactly spherical but the particles could be distinctly seen as revealed from TEM photograph. The cytotoxicity was done on Caco2 cell line by MTT assay at STA concentration of 10, 50 and 100 nM. The cell toxicity was found to be 10) was shown to be more resistant towards latex DCS treatment compared to those of early passages (P30. Conclusion: Late passage CAL-27 cells have been shown to exhibit cancer stem cell characteristics, particularly on that of treatment resistance, migration ability and phenotype reversibility. Keywords: CAL-27 cell line, treatment resistance, migration, phenotype reversibility

74

P-06 Cytotoxic effect of Apigenin on MCF-10A, MDA-MB-231, MCF-7 and bone marrow stem cells Chan Mooi Kwai, Chew Ai Lan, Rahman Noordin, Khoo Boon Yin Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia Email: [email protected]

Abstract Introduction: Apigenin is one of the common flavonoids found in many fruits and vegetables. Studies have proved that apigenin has anticancer properties in which it could suppress the growth of many human cancer cells. Aim: Our study aims to evaluate the cytotoxic effect of apigenin on four types of human cells; human breast epithelial cells (MCF-10A), human estrogen negative breast cancer cells (MDA-MB231), human estrogen positive breast cancer cells (MCF-7) and human bone marrow stem cells. Methodology: The cells were first treated with different concentration of apigenin; 0 µM, 10 µM, 25 µM, 50 µM, 100 µM and 200 µM for 24 hours, 48 hours and 72 hours. The level of lactate dehydrogenase (LDH) released from each apigenin treated cells was then determined using Cytotoxicity Detection Kit. DMSO was used as vehicle solvent in this study. Results: Two-way ANOVA analysis showed no significant cytotoxic effect was observed on MCF-10A treated with apigenin at concentrations below 50 μM, at all time points. However, the cytotoxic effect was observed on MCF10A treated with 100 μM and 200 μM apigenin at 72 hours. Treatment of MDA-MB231 with apigenin showed cytotoxic effect at about 10-20% for all time points. However, this effect was not statistically significant. MCF-7 showed significant cytotoxic effect at an elevated level when the cells were treated with 100 μM and 200 μM apigenin at all time points. This phenomenon was not observed in the apigenin treated bone marrow stem cells. The treated stem cells showed significant cytotoxic effect on the stem cells that were treated with 200 μM apigenin only at 24 hours onwards. Concentration: In conclusion, apigenin may be useful for inhibiting the growth of estrogen positive breast cancer cells in human at concentrations below 100 μM for treatment of at least 48 hours.

75

P-07 The effect of Seaweed (Eucheuma cottonii) on mammary carcinogenesis in rats Chang Vi Sion, Teo Swee Sen UCSI University, Kuala Lumpur Campus, Malaysia Email: [email protected]

Abstract Marine macroalgae and microalgae are abundantly used as food and medicine around the world. The edible red seaweed (Euchuema cottonii) is one of the algae species which was found to be rich in nutrients and polyphenolic compounds. Hence, E. cottonii may have the ability to suppress cancer through its antioxidant and antiproliferative properties. Thus, the aim of this study was to determine the effect of E. cottonii on 7, 12-dimethylbenz[a]anthracene (DMBA) mammary carcinogenesis in rats. This study was consisted of three groups of experimental, untreated and normal group of rats. The experimental and untreated groups of rats were induced with mammary tumour with DMBA. In order to investigate the anticancer effect of the E. cottonii, the experimental group of rats was orally gavaged with E. cottonii crude extract. The results were being used to compare with untreated group of rats and normal group of rats. All the rats were fed with standard diet and water ad libitum. Mortality, behaviour changes, body weight and tumour sizes were observed specifically. The differences between the three groups of rats were evaluated using the ANOVA test. The tumour size in the untreated group of rats was found significantly larger than the experimental group of rats where the rats were treated with E. cottonii crude extract (p = 0.017). Besides that, the white blood cells level in the untreated group rats was found significantly higher than the experimental group of rats and the normal group of rats (p = 0.002). There was no significance found in the haematological values and biochemical values among the three groups of rats throughout the study. However, there was a significant result showing that the E. cottonii extract was able to slow down the growth rate of the tumour cells. Therefore, identification of inhibitory growth rate of an active compound on tumour cells can be positively carried out in the future case study.

76

P-08 Phosphorylation of AKT and GSK3β promotes the proliferation of CAL27 cell line 1

1

2

Chow Tan Wei , Ong Ming Thong , Shaharum Shamsuddin 1 Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia 2 School of Health Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia Email: [email protected]

Abstract Introduction: Oral carcinogenesis is a multi-step process that requires the accumulation of genetic alterations in a single cell, resulting in the loss of cell cycle checkpoints. AKT is activated by phosphorylation at Thr308 and Ser473. GSK3, a substrate for AKT in phosporylation process, plays an important role in WNT signalling pathway. The regulated phosphorylation of GSK3β at Ser9 by AKT leads to various oncogenic responses that are frequently reported in oral squamous cell carcinoma. Objective: In order to study the growth promoting roles of AKT and GSK3 in CAL27 (oral squamous carcinoma cell line), stable mutant CAL27 cell lines with knocked-down AKT and GSK3β were established. Methodology CAL27 was stably transfected with PPpBabe/Akt and pBabe/GSK3β . The resulting mutant proteins would have specific disrupted phosphorylation sites, preventing these from carrying out normal functions. The potential clones were selected using puromycin and expression of mutant protein was confirmed by Western blot. Cell proliferation assay was conducted with mutant cell lines to evaluate the growth rate of the mutated cell lines. Results: Four PPCAL27/AKT clones and six CAL27/GSK3β clones were selected and all of them showed a slower cell proliferation rate compared to non-mutant CAL27. Conclusion: AKT and GSK3β have been shown to be essential in promoting cell proliferation in CAL27, a cancer-origin cell line, and hence the expression level of these could be a Puseful tool in early oral cancer detection. The establishment of stable AKT and PGSK3β oral cancer cell lines could also serve as a model in cancer therapeutic study.

77

P-09 An immuno-epidemiological survey for Schistosoma infection in Sudan and detection of colorectal cancer in Schistosoma Mansoni infected patients 1

2

2

1

Eshtiyag A. Abdalkareem , Abdulla H. Sharif , Ahmad Babiker , Khoo Boon Yin 1 Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia 2 Tropical Medicine Research Institute (TMRI), P.O. Box 1304, Khartoum, Sudan Email: [email protected]

Abstract This study was conducted in two camps in Tayba Elshaikh Elgorashi village area in the northern part of Gazira Scheme in Central Sudan. The inhabitants of both camps are field agricultural labourers. The objectives of the study were to determine the indices of schistosomiasis infection among the populations of the two camps and the immune responses due to the infection and to determine the percentage of people with colorectal cancer at the same time they are chronically infected with Schistosoma mansoni. The prevalence of S. mansoni infection in Elshajara camp was 58.4%. In Hababna camp, the prevalence of S. mansoni infection was 48.4%, the two camps showed a reduction than that reported previously. The reduction in both camps was significant. The prevalence of S. haematobium infection in Hababna camp was 33.7%. The presence of the urinary species was reported for the first time in the area. Individuals less than 15 years old showed the highest prevalence of infection compared with other age groups. The history of infection with Schistosoma was indicated by about 20% of the study group. There were no gender significant differences in Hababna camp. In this study specific IgG and IgE responses to adult worm antigen (SWA) were determined. High levels of anti-Schistosoma IgG among all volunteers of the two camps were recorded when compared with anti-Schistosoma IgE levels. There were significant differences in the levels of IgG and IgE of those infected with S. mansoni and the non-infected. Both IgG and IgE levels were high in the noninfected when compared with those infected with S. mansoni. On the other hand, no such differences were observed in those infected with S. haematobium in their IgG and IgE levels. Children in age group 4-15 years seemed to have the highest prevalence of infection when compared with other age groups, and they had the highest levels of IgG and IgE. These study records there have 40 patients with chronic S. mansoni infection have colorectal cancer.

78

P-10 The use of Tc-99m radioisotope as early lymph diagnosis for breast cancer Fahrunissa Niniez Winner, Risha Diah Rhamadhani Polytechnic Institute of Nuclear Technology (STTN), Batan, Indonesia Email: [email protected]

Abstract Nowadays, the countries such as Indonesia, Australia, New Zealand, and Western Europe face a serious threat to the lives called “cancer”. In Latin "Mens Sana in corpore Sano", which means, "in a healthy body there is a strong soul", describes that in a strong soul there is a healthy mind, healthy mind could perform positive actions, and the actions will positively make us, the family, environment, and society more advanced. In summary, health can be made immune to diseases. Cancer treatment has become more creative, including through methods called lymphoscintigraphy. This method is based on nanocolloid utilizing Technetium –99 m radioisotope. Diagnosis is done by injecting a radiopharmaceutical preparation in nano-sized (100-200 nm). Thus, size is intended to provide assurance that the measurement obtained will be more homogeneous, because the range is relatively smaller, so their retention in the lymph channels could be better. In addition, the movement of nanocolloid marked with Technetium -99 m radiopharmaceutical will be detected from outside the body using a gamma camera. Lymphoscintigraphy is recommended as a complementary diagnostic method to determine the state of the lymphatic channels in breast cancer patients. The success of a surgery or breast cancer therapy can be monitored by looking at the sentinel nodes in patients’ lymphatic channels, so the follow-up surgery or other forms of treatment can be designed and run as it should. Keywords: Breast cancer, Health, Lymph, Treatment

79

P-11 Synthesis of chlorogenic acid-magnesium/aluminium layered double hydroxide nanocomposite as an anticancer nanodelivery system 1

1

2

Farahnaz Barahuie , Mohd Zobir Hussein* , Palanisamy Arulselvan , 2,3 1 Sharida Fakurazi , Zulkarnain Zainal 1 Materials Synthesis and Characterization Laboratory, Institute of Advanced 2 Technology (ITMA), Laboratory of Vaccines and Immunotherapeutics, Institute of 3 Bioscience, Department of Human Anatomy, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia (UPM), Serdang, Selangor, Malaysia Email: [email protected]

Abstract Introduction: Cancer is still the leading cause of death in many countries. However, the effectiveness of the drug treatment is limited due to inability to access and penetrate the target cancer cells or nonspecific. Nanomaterials could be used as vectors so that they are more effective and specific. Therefore, these delivery systems are necessary for new generation of therapeutic materials with full efficacy. Inorganic nanomaterials, such as layered hydroxides (LDH) were found to be excellent as drug delivery agents. They are biocompatible and biodegradable and have strong tendency to release the drug in a controlled manner. Objectives: The objectives of this work are to synthesise a nanodrug delivery system of an anticancer agent, chlorogenic acid by intercalation of the drug into Mg/Al -LDH interlamellae and study their controlled release and cytotoxicity properties. Methods: Chlorogenic acid was intercalated into 2D nanolamellae of Mg/Al-NO3-LDH by direct, co-precipitation and indirect, ion-exchange techniques, for the formation of new nanocomposites, CMAC and CMAE, respectively. In vitro anticancer properties of both nanocomposites against human cancer cells namely MCF-7, HeLa, HepG2, A549 and normal fibroblast cells, 3T3 were investigated by cell cytotoxicity assay. Results: The formation of new nanocomposites containing chloeogenic acid, CMAC and CMAE, was confirmed by x-ray diffraction and Fourier transform infrared studies, with loading percentage of 54.2% and 37.3% of chlorogenic acid, respectively. The release of chlorogenate in phosphate buffered solutions occurred in a controlled manner, governed by pseudo-second order release mechanism. The nanocomposites showed better cytotoxicity properties against the cancer cells particularly the liver cancer cells, HepG2 in a dose-dependent manner. The nanocomposites did not produce any toxicity behaviour in normal fibroblast cells. Conclusion: This preliminary investigation suggests that the nanocomposites showed anticancer properties against the cancer cells without showing any toxicity to normal fibroblast cells. 80

P-12 Preliminary screening of edible plants for cytotoxic activity on human colorectal carcinoma (HT29) cell line and antioxidant property Gartheka Ganasen, Yuhasini Thuraisingam, Kokila Thiagarajah, Norliza Shah Jehan Muttiah Department of Biomedicine, Universiti Tunku Abdul Rahman Email: [email protected]

Abstract In Malaysia, the incidence of colorectal cancers has been mounting slowly due to the changes in the diet such as increase in fat and decrease in dietary fibre which predispose people to colorectal cancer. Recent studies showed that medicinal plants are not only can be used as food ingredients, but also can benefit human health. In this respect, the present study has been designed to explore the cytotoxic and antioxidant activities of a few medicinal plants traditionally being used in treatment of various ailments in Malaysia. The ethanolic extracts of nineteen plants including Aegle marmelos, Ocimum sanctum, Zingiber officinale, Curcumin, Centella asiatica, Chrysanthemum indicum, Sesbania grandiflora, Nasturtium officinale, Cymbopogon citrates, Morinda citrifolia, Piper sarmentosum Roxb, Moringa oliefera, Polygonum minus, Vitex negundo, Parkia speciosa, Psidium guajava, Myristica Fragrans, Etlingera elatior and Citrus hystrix were evaluated for their in vitro cytotoxicity and antioxidant activity using 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) cell viability assay on HT29 cancer cells and1-diphenyl-2-picrylhydrazyl radical (DPPH), respectively.

81

P-13 Zerumbone inhibits murine WEHI-3B cells in BALB/c mice in vivo 1,2

1,2

2

Heshu Sulaiman Rahman , Rasedee Abdullah , Ahmad Bustamam Abdul , 1 1,2 2 Hemn Hassan Othman , Zeenathul Nazariah Allauddin , Negin Ahmadi 1 2 Faculty of Veterinary Medicine and Institute of Bioscience, University Putra Malaysia (UPM), Serdang, Selangor, Malaysia Email: [email protected]

Abstract Zerumbone is a crystalline, monocyclic, sesquiterpene, phytochemical, natural dietary substance first isolated from essential volatile oil of rhizomes from the edible wild ginger, Zingiber zerumbet (L.) smith. Several pharmacological potentials of zerumbone were identified through several test models including potent and strong anticancer activity in vitro. However, there is no report addressing whether zerumbone affects murine leukaemia cells or immune responses in vivo. Herein, this study focused on the in vivo effects of zerumbone on WEHI-3 leukaemia in mice. The results indicated that zerumbone reduced spleen weight and increased the percentage of cells with CD3 and CD19 markers, indicating that differentiation of the precursors of T- and B-cells was promoted in the leukemic mice. Finally, we concluded that ZER might be useful to be developed as a safe anticancer agent for treating of acute myelocytic leukaemia (AML).

Keywords: Zerumbone, BALB/c mice, Immunophenotyping

82

P-14 Anticancer activity of proteins extracted from Gynura procumbens 1

2

1

Hew Chaw Sen , Khoo Boon Yin , Gam Lay Harn 2 School of Pharmaceutical Sciences and Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia Email: [email protected]

1

Abstract Introduction: Gynura procumbens is a herb that is used traditionally to treat high cholesterol level, high blood pressure, diabetics, inflammation and cancer in South East Asia. Using proteomic approach, our earlier study showed the presence of some valuable plant defence proteins, such as peroxidase, thaumatin-like protein and miracullin in the leaf of G. procumbens. Objective: We aimed to analyze cytotoxic activity of the protein extracted from the leaves of G. procumbens and subsequently to determine the route of cytotoxicity mechanism through the expression of proliferation and invasion markers in the treated MDA-MB-231 breast cancer cell line. Methods: Leaf protein was extracted by mild phosphate buffer. The protein extract was purified by ammonium sulphate precipitation method and then fractionated according to sizes using gel filtration chromatography. Cytotoxic activity of the purified protein fraction against MDA-MB-231 was determined using lactate dehydrogenase (LDH) cytotoxicity assay. The expression of proliferation markers, Ki67 and PCNA and invasion markers, CCL2 and IL-6 in the MDA-MB-231 protein fraction treated cells were determined using semi-quantitative polymerase chain reaction (PCR). Results: The purified protein fraction, SN-F11/12 was found to inhibit the growth of MDA-MB-231 at an EC50 value of 3.8 µg/mL. The mRNA expression of Ki67 and PCNA were reduced significantly in the MDA-MB-231 treated with SN-F11/12. The mRNA expression of CCL2 was also found reducing in the treated MDA-MB-231. Conclusion: The SN-F11/12 can be potentially used as protein-based chemotherapeutic agent against breast cancer.

83

P-15 Studying the expression of PPAR and its associated genes at mRNA level in MDA-MB-231 cells treated with pioglitazone and MK886 1

1

2

Kalpanah Nadarajan , Chew Ai Lan , Elena Elstner , Khoo Boon Yin 1 Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia 2 Division of Oncology and Haematology, Charité Campus Mitte, Humboldt University of Berlin, Germany. Email: [email protected]

1,2

Abstract Introduction: Peroxisome proliferator-activated receptor alpha (PPAR) is a transcription factor regulates lipid metabolism. Previous studies show that PPAR is dynamically regulated in MDAMB-231 breast cancer cells whereby it increases proliferation of the breast cancer cells. Pioglitazone is a prescription drug of class thiazolidinedione (TZD) used in the treatment of type II diabetes. Pioglitazone regulates PPAR by altering regulatory proteins or inducing endogenous PPAR agonists. On the other hand, MK886 is an indole derivate that acts as an antiproliferative drug which induces apoptosis in various cancer cells, as reported previously. MK886 has been widely used in scientific studies as PPAR antagonist. It is hypothesized that PPAR expression influences cellular processes such as proliferation, differentiation and invasion. Objective: The present study determined the expression of PPAR and its regulation effect on other target genes in MDA-MB-231 cells treated with pioglitazone and MK886 using real-time PCR. Methods: For this purpose, in vitro culture of MDA-MB-231 cells were first treated with pioglitazone and MK886, and the total RNA of the cells post treatment with pioglitazone and MK886 were extracted and the RNA was synthesized into cDNA. The cDNA was then used to determine the mRNA expression levels of PPAR and its associated target genes using Realtime PCR. Results: From the PCR results observed, PPAR was upregulated in MDA-MB-231 cells treated with 30 mM of pioglitazone for 6 days. However, the expression of the gene was downregulated in the cells treated with 3 mM of MK886 for 6 days. The Real-time PCR results indicated also that PPAR, IL-6, 5-Lipoxygenase were highly upregulated in the MDA-MB-231 cells post pioglitazone treatment for 6 days. Interestingly, the expressions of these target genes were showed reducing in MDA-MB-231 cells treated with MK886 for 6 days. Moreover, FGF4 was moderately upregulated in MDA-MB-231 cells post both treatments for 6 days. Additionally, the mRNA expression level of apoptotic genes, such as Caspase-3 and Caspase-9, were observed slightly higher in MDA-MB-231 cells treated with pioglitazone and MK886, respectively, for 6 days, when compared to the control cells. 84

Conclusion: The mechanisms involving PPAR, IL-6 and 5-Lipoxygenase in MDA-MB-231 cells treated with pioglitazone and MK886 could be PPAR-dependent. However, future studies that may provide more useful information on the expression of PPAR in estrogen receptornegative human breast cancer cells are warranted. Keywords: Pioglitazone, MK886, PPAR, breast cancer cells

85

P-16 In vitro anticancer activity of traditional medicinal plants against cancer cell lines Kavitha Nowroji, Oon Chern Ein, Sasidharan Sreenivasan Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Penang, Malaysia Email: [email protected]

Abstract Introduction: Medicinal plants have been identified and used throughout human history since plants have the ability to synthesize a wide variety of chemical compounds that are used to perform important biological functions. However, scientific research is important in the evaluation of traditional claims for treatment of ailments of infectious diseases. Objective: The objective of the study was to determine the anticancer activity of two commonly used medicinal plants in Malaysia, Phaleria macrocarpa (Scheff.) Boerl (Thymelaceae) is known as ‘Mahkota Dewa’ and Cassia spectabilis (sin Senna spectabilis) (DC). Methods: P. macrocarpa fruit ethyl acetate extract (EAPM) and C. spectabilis methanol leaf extract were screened in vitro by using tetrazolium dye MTT;3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide for their anticancer activity against two breast cancer cell lines (MCF-7;ER positive and MDA-MB-231; ER negative) and normal cell lines (Vero; African green monkey kidney cells). MTT assay revealed significant anticancer activity against MDA-MB-231 followed by MCF-7 when tested with EAPM extract and C. spectabilis methanol leaf extract, respectively. Vero cell lines were used as positive control. Results: EAPM extract demonstrated highest anticancer activity against MDA-MB-231 with the IC50 value of 18.88 µg/ml and followed by MCF-7 with IC50 of 51.57 µg/ml. Moreover, the EAPM extract also did not show any toxicity against Vero cell lines with IC50 value of 124.47 µg/ml which is considered safe to normal cell lines, whereas C. spectabilis methanol leaf extract did not exhibit any anticancer activity against both breast cancer cell lines. Conclusion: Therefore, our results suggested that EAPM extract could be a good candidate for developing anticancer agent.

86

P-17 Targeted delivery of anticancer drug with anti-angiogenic dendrimers for effective cancer treatment Keerti Jain, Narendra Kumar Jain Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour University, Sagar (M.P.), India Email: [email protected]

Abstract Introduction: Dendrimers are extensively being investigated in therapy of cancer. Recently poly-l-lysine (PLL) dendrimers have been reported to show anti-angiogenic activity. Objective: In the present study, we report folic acid conjugated PLL dendrimers (FPLL) as an efficient carrier for model anticancer drug, doxorubicin hydrochloride (Dox), along with pH sensitive drug release, selective targeting to cancer cells, anticancer activity and anti-angiogenic activity. Methods: PLL dendrimers were synthesized by divergent synthesis method and conjugated peripherally with folic acid. Conjugation of folic acid to PLL dendrimers was confirmed by IR, NMR, ESI-MS, TEM and AFM. Drug was loaded in FPLL dendrimers by equilibrium dialysis method and developed formulation was evaluated for entrapment efficiency, hemolytic toxicity, in vitro drug release, anti-angiogenic activity, ex vivo anticancer activity and cell uptake studies using MCF-7 cancer cell lines. In vivo pharmacokinetic, bio-distribution and anti-tumour activity studies were performed on tumour xenograft model. Results: In the in vitro release profile, this nanoconjugate of Dox showed initial rapid release with gradual slow release. Further drug release was found to be pH sensitive with faster release at acidic pH. In the CAM assay and tubule formation assay with HUVEC, Dox-FPLL formulation showed significant anti-angiogenic activity. The ex vivo investigations with MCF-7 cancer cell lines showed enhanced cytotoxicity with DoxFPLL with significantly enhanced intracellular uptake (p